



# Maternal Nutrition During Gestation Alters Histochemical Properties, and mRNA and microRNA Expression in Adipose Tissue of Wagyu Fetuses

Yi Zhang<sup>1,2</sup>, Konosuke Otomaru<sup>3</sup>, Kazunaga Oshima<sup>4</sup>, Yuji Goto<sup>4</sup>, Ichiro Oshima<sup>1</sup>, Susumu Muroya<sup>5</sup>, Mitsue Sano<sup>6</sup>, Sanggun Roh<sup>7</sup> and Takafumi Gotoh<sup>1,2\*</sup>

#### **OPEN ACCESS**

#### Edited by:

Takahiro Nemoto, Nippon Medical School, Japan

#### Reviewed by:

Elke Albrecht, Leibniz Institute for Farm Animal Biology (FBN), Germany Stephen Brent Smith, Texas A&M University, United States

> \*Correspondence: Takafumi Gotoh gotoh@agri.kagoshima-u.ac.jp

#### Specialty section:

This article was submitted to Experimental Endocrinology, a section of the journal Frontiers in Endocrinology

Received: 19 October 2021 Accepted: 15 December 2021 Published: 01 February 2022

#### Citation:

Zhang Y, Otomaru K, Oshima K, Goto Y, Oshima I, Muroya S, Sano M, Roh S and Gotoh T (2022) Maternal Nutrition During Gestation Alters Histochemical Properties, and mRNA and microRNA Expression in Adipose Tissue of Wagyu Fetuses. Front. Endocrinol. 12:797680. doi: 10.3389/fendo.2021.797680 <sup>1</sup> Faculty of Agriculture, Kagoshima University, Kagoshima, Japan, <sup>2</sup> Kuju Agricultural Research Center, Kyushu University, Taketa, Japan, <sup>3</sup> Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan, <sup>4</sup> Western Region Agricultural Research Center, National Agriculture and Food Research Organization (NARO), Oda, Japan, <sup>5</sup> Institute of Livestock and Grassland Science, National Agriculture and Food Research Organization (NARO), Tsukuba, Japan, <sup>6</sup> Department of Nutrition, School of Human Cultures, The University of Shiga Prefecture, Hikone, Japan, <sup>7</sup> Graduate School of Agricultural Science, Tohoku University, Sendai, Japan

We hypothesized that maternal low or high nutrition would give unique effects to morphological and molecular dynamics in adipose tissue of fetus of fatty breed Wagyu (Japanese Black) cattle which produce highly marbled beef. This study aimed to determine the effects of maternal energy intake in Wagyu cows, during gestation on fetal adipose tissue development, histochemical properties, and gene and microRNA (miRNA) expression. Cows were allocated to one of two nutritional energy groups: 120% (HIGH) or 60% nutritional requirements of (LOW). Fetuses (n = 6 per treatment) were removed from pregnant cows by cesarean section at fetal age  $260 \pm 8$  days and euthanized. Subcutaneous adipose tissue (SAT), thoracic cavity visceral adipose tissue (TVAT), and perirenal adipose tissue (PAT) were collected for analysis. In histochemical analysis, in SAT and PAT, HIGH fetuses had greater diameter of adipocytes than LOW fetuses (P<0.05). Only in SAT, LOW fetuses had more Leptin (LEP) mRNA and tended to have more Peroxisome Proliferator-Activated Receptor gamma (PPARG) CCAATenhancer-binding proteins alpha (CEBPA) and Glucose transporter (GLUT) 4 mRNA (P<0.10). In all SAT, TVAT, and PAT, LOW fetuses had higher levels of the brown adipose tissue (BAT) biomarkers Uncoupling Protein (UCP) 1 and PPARG coactivator (PGC)  $1\alpha$ mRNA than HIGH fetuses (P<0.08). Meanwhile, in the other adipose tissue, LOW fetuses had lower PPARG, CEBPA, and Zinc Finger Protein (ZFP) 423 (in TVAT and PAT), FASN (in TVAT), LEP and GLUT4 mRNA (in PAT; P<0.10). In particular, in TVAT and PAT, LOW fetuses exhibited lower expression of WAT biomarkers (PPARG and ZFP423). Differential expression of various miRNAs related to adipogenesis between the LOW and HIGH

fetuses was detected in an adipose tissue-specific manner (P<0.10). Based on adipose tissue-specific effects of maternal nutrition, these findings suggested that poor maternal nutrition in Wagyu cattle increased BAT development in SAT, TVAT and PAT, while elevated maternal nutrition stimulated fetal SAT development compared with that of TVAT and PAT.

Keywords: maternal nutrition, Wagyu fetus, adipose tissue, gene expression, histochemical property

# INTRODUCTION

Through its major contribution as a source of protein in people's diets, beef plays an important role in human health. To improve meat quality-related factors such as juiciness and flavor, intramuscular adipose tissue is crucial (1, 2). However, adipose tissue in carcasses, that is, SAT, renal adipose tissue, and intermuscular adipose tissue, is basically useless or wasted adipose tissue from the perspective of human consumption. Actually, we partly use Wagyu adipose tissue as a material for processed beef in Japan, however a huge amount of wasted adipose tissue is still abandoned. Wagyu (Japanese Black) cattle have not only a greater percentage of intramuscular fat but also a greater mass of carcass adipose tissue than European cattle (3). Although Wagyu is a unique animal model regarding obesity and intramuscular fat accumulation, we would like to shift the focus on its development from increasing intramuscular fat to instead reducing wasted adipose tissue. However, the molecular mechanism behind the accumulation of such adipose tissue in cattle is unknown.

Adipose tissue is scattered throughout the body but comprises 5% to 35% of cattle body mass, depending on age, genotype, and nutrition (4). In terms of the anatomically distinct sites where adipose tissue develops, there are three major sites of accumulation, visceral, subcutaneous, and intermuscular, which are further subdivided into smaller depots defined by anatomical location. The formation of discernible adipocytes begins midgestation in beef cattle (4-6). Prior and Laster (7) confirmed that the maternal period during mid- to late gestation in cattle is crucial for adipose tissue development. Additionally, during fetal muscle development, a small portion of the progenitor cells differentiate into adipocytes, which also form intramuscular fat and marbling in the offspring (8). Some studies have demonstrated that the manipulation of maternal nutrition, including over- and undernutrition during gestation, impacts on adipose tissue development and the expression of adipogenesis marker genes in fetuses (4, 9, 10). This suggests that maternal nutrition during gestation plays an important role in adipose tissue development in fetuses.

There are two types of adipose tissue in mammals, white adipose tissue (WAT) and brown adipose tissue (BAT), which have markedly different morphological roles and biological functions (11). In newborns, BAT is essential for ensuring effective adaptation to the extrauterine environment, and the growth of both WAT and BAT during gestation is largely dependent on the supply of nutrients from mother to fetus (12). There are differences of depots place between rodents (interscapular), large mammals and human (around the central organs and supraclavicular region; 12). Change in maternal nutrition at defined stages of gestation would ultimately have long-term adverse effects on the offspring by modifying normal profiles of adipose development. For example, suboptimal maternal nutrition during early to mid-gestation was reported to result in excess macrophage accumulation and the onset of insulin resistance in an adipose tissue depot-specific manner in offspring (12).

At the molecular level, many important factors involved in adipogenesis have been found (PPARG, CEBPA, Stearoyl-CoA desaturase (SCD), Fatty acid synthase (FASN), Fatty acid binding protein (FABP) 4, LEP, TNFa, and ZFP423) (13-17), and in recent years factors involved in the development of brown adipocytes (Uncoupling protein (UCP) 1, PR/SET domain (PRDM) 16, and PGC1 $\alpha$  have also been identified (18). Factors related to adipocyte development and metabolism (IGF1, IGF2 GLUT4, INSR, IRS1 PI3K, AKT1, AKT2, and mTOR1) have been considered (19-22). Furthermore, as another factors affecting these genes expression, miRNAs (miRNA-15b, 16 b, 19b, 27b, 33a, 101, 130a, 148a, 152, 196a, 204, 296-3p, and 378) have been noticed (23-33). It has been still unclear how maternal nutrition affects these factors in fetal adipose tissues of Wagyu cattle and its differences among different adipose depots.

We also previously demonstrated that Wagyu cows fed diets with reduced [60% of nutritional requirement: Japan Feeding Standard for Beef Cattle (34;JSFBC)] and slightly greater than required nutritional content (120% of nutritional requirement: JSFBC) from pre-conception to gestational day 260 produced fetuses with phenotypic differences, including fetuses from the latter group having greater adipose tissue mass (2.12-fold), muscle mass (1.42-fold), bone mass (1.24-fold), and fetal body weight (1.39-fold; 35). Several ruminant groups were used to examine the impacts of under- and overnutrition on fetal development; few phenotypic differences in fetuses were identified, although there were differences in gene expression in muscle (36-40). Fetuses with different phenotypes were obtained by different maternal nutrition during gestation (35), these differences might alter the metabolic rate of the whole fetus and change adipose tissue metabolism. We hypothesized that inadequate maternal energy status would alter fetal adipose tissue development in an adipose tissue depot-specific manner in Wagyu fetuses. The objective of this study was thus to determine the consequences of higher or lower maternal energy status throughout gestation on Wagyu fetuses as follows: 1) on the morphology of adipocytes in SAT, and PAT;

and 2) on the expression of genes and miRNAs related to growth, adipogenesis, and glucose metabolism in SAT, TVAT, and PAT.

## MATERIALS AND METHODS

## Animals, Diets, and Experimental Design

The animal study was reviewed and approved by Kagoshima University Animal Care and Use Committee (A18007). Written informed consent was obtained from the owners of the animals for their participation in this study. The experimental details were previously reported elsewhere (35). Briefly, multiparous Wagyu cows (n = 32) were obtained from Kagoshima University Iriki farm (n = 12) and Western Region Agricultural Research Center (n = 20). The cows were randomly assigned to two dietary treatment groups matched for body mass: diets formulated to meet either 60% (LOW) or 120% (HIGH) of their Japan Feeding Standard for Beef Cattle (34)-predicted energy requirements using formula feed. All cows were housed in a drylot, and diets were individually provided twice daily for 2 months prior to and throughout gestation using stanchions that locked each cow in until all feed had been consumed.

The total mixed ration consisted of whole-crop silage, composed of rice plants, dried timothy grass, rye straw, brown rice, beer lees, sugar cane pellets, tofu lees, soy sauce cake, sugar cane bagasse, rice bran, corn steep liquor, condensed sweet potato distillers' solubles, rice trienol, calcium, and water. The final crude nutrient composition of mixed feed, on a dry-matter basis, was 56.1% NDF, 36.0% ADF, 11.1% ash, 8.00% crude protein, 0.60% calcium, and 0.30% phosphate. The metabolizable energy provided by the feed was 8.56 MJ/kg dry matter.

All cows were synchronized using a controlled internal drug release device (Easybreed, InterAg Co. Ltd., Hamilton, New Zealand). All cows were inseminated with frozen male-sorted semen from the same sire (Yurikatsuyasu, Kedaka line) to produce half-brothers and to minimize other influencing effects except for nutritional status. After breeding, six cows from each group became pregnant.

## **Slaughter and Sample Collection**

Maternal body weight was measured every month from the start of the study until cows were transported to Kagoshima University Veterinary Teaching Hospital on day  $260 \pm 8.3$  of gestation. Fetuses were obtained by cesarean section and euthanized. The fetal body weight, and weights of carcass muscle, carcass bone, and adipose tissue depots including SAT, TVAT, and PAT were measured as described by Zhang et al. (35).

## Sample Processing

SAT was collected from total adipose tissue between skin and the outermost parts of skeletal muscle from the right carcass to measure the weight. SAT samples for histochemical and molecular analysis were taken from adipose tissue located around between forelimb and body trunk. TVAT was collected from the thoracic and visceral cavity of the right-side carcass, and PAT was taken from adipose tissue covering the left kidney.

The fetal adipose tissue was dissected free of other connective tissue and these samples for histological analysis were immediately covered with Tissue Tek (tissue freezing medium; Sakura Fine Technical, Tokyo, Japan), rinsed in ice-cold saline, snap-frozen in liquid nitrogen, and stored at  $-80^{\circ}$ C until use.

## Histochemical and Immunohistochemical Analyses

A 1-cm<sup>3</sup> core of adipose tissue from SAT, TVAT and PAT, immediately covered with tissue freezing medium (Tissue Tek; Sakaura Fine Technical, Tokyo, Japan), snap-frozen in liquid nitrogen, and stored at  $-80^{\circ}$ C until analysis. Adipose tissue samples were sectioned at 10-µm thickness using a cryostat microtome CM3050 S (Leica, Bensheim, Germany). These sections were fixed by 10% formaldehyde and stained by using Harris Modified Hematoxylin (Fisher Scientific, Fair Lawn, NJ, USA) and Eosin Y (EMD Chemicals, Gibbstown, NJ, USA).

Rabbit polyclonal antibody to human Ucp1 (ab10983) was obtained from Abcam (Cambridge, MA, UK) to examine immunolocalization in the SAT, TVAT, and PAT. According to the manufacturer, this antibody was predicted to recognize bovine Ucp1 (41). Endogenous peroxidase was blocked using BLOXALL<sup>TM</sup> Endogenous Peroxidase and Alkaline Phosphatase Blocking Solution (Vector Laboratories, Inc., Burlingame, CA, USA) for 10 min at room temperature. The sections were washed with PBS and treated using VECTASTAIN ABC Kit, Peroxidase (Rabbit IgG) (Vector Laboratories, Inc.). In accordance with the manufacturer's instructions, normal goat serum blocking solution was applied for 20 min at room temperature. After washing with PBS, the sections were incubated with the anti-Ucp1 antibody (diluted 1:400) overnight at 4°C. The sections were then washed with PBS and incubated with a biotinylated goat anti-rabbit secondary antibody for 30 min at room temperature. After washing with PBS, the sections were incubated with peroxidaseconjugated streptavidin for 30 min at room temperature. After washing with PBS, the DAB substrate kit (Nichirei Biosciences, Tokyo, Japan) was applied to the sections for 5 min at room temperature, followed by counterstaining with hematoxylin. The sections were then dehydrated and mounted. The experiments were repeated at least three times and the positive staining was reproducibly detected. The sections were captured with an BZ-X800 ALL-IN-ONE fluorescence microscope (Keyence, Tokyo, Japan) under the same microscope objective (30×), and five randomly chosen fields were taken per section for a total of 20 images per animal. Images were randomly selected for analysis, the diameter of adipocytes based on the average of maximum dimension of the long axis and that of the axis perpendicular to the long axis was calculated for at least 50 cells per field area, and at least 250 adipocytes were measured per animal via image analysis using CELL image analysis software (Keyence, Tokyo, Japan) and the cross-sectional area (CSA) of adipocyte was calculated by using the average of the diameter.

# Total RNA Extraction and Real-Time qPCR

Total RNA from each adipose tissue was extracted from less than 100 mg of tissue using miniRNeasy Lipid Tissue Kit (Qiagen,

Germantown, MD, USA), in accordance with the manufacturer's instructions. Total RNA samples were quantified using a spectrophotometer (ND-1000; NanoDrop, Wilmington, DE, USA). The purity of RNA ( $A_{260}/A_{280}$ ) for all samples was above 1.9 and the RNA was stored at  $-80^{\circ}$ C until cDNA synthesis. Total RNA (500 ng) from each individual calf and tissue was reverse-transcribed with the High-Capacity cDNA Reverse Transcription Kit (Life Technologies Inc., Carlsbad, CA, USA), in accordance with the manufacturer's instructions. The RT products (cDNA) were stored at  $-30^{\circ}$ C for relative quantification by PCR.

The primers were designed using Primer Express 3.0 with a minimum amplicon size of 80 bp (when possible, amplicons of 100-200 bp were chosen), and aligned against publicly available databases using BLASTN (Basic Local Alignment Sequence Tool for Nucleic Acid) at the website of the National Center for Biotechnology Information (NCBI; Bethesda, MD, USA; Table 1). Before qPCR, primers were tested in a 20 µl PCR reaction using the same protocol as described for qPCR except for the final dissociation protocol. For primer testing, we used a universal reference cDNA (RNA mixture from four different bovine tissues) to ensure identification of the desired genes. A total of 5 µl of the PCR product was run in a 2% agarose gel stained with ethidium bromide (2 µl). The remaining 15 µl was cleaned using the QIAquick PCR Purification Kit (Qiagen). Only those primers that did not present as a primer-dimer, had a single band at the expected size in the gel, and had the right amplification product (verified by sequencing) were used for qPCR. The accuracy of each primer pair was also evaluated by the presence of a unique peak during the dissociation step at the end of quantitative PCR (qPCR).

Real-time PCR analysis was performed in triplicate using 100 ng of cDNA in 96-well fast plates using the SYBR Fast Master Mix ABI Prism (D-Mark Biosciences, Toronto, Canada) and the Step-One Plus Real-time PCR system (Life Technologies Inc.). A blank sample and a minus RT were added to control for nonspecific amplification. Relative standard curves, made from a serial dilution of pooled cDNA from the tissue of interest and ranging from 20 to 0.02 ng, were used to determine the relative quantity of each sample. The amplification efficiency for each gene was determined using serial dilution of tissue-specific cDNA and was found to be 100 ± 10% for all genes. The resulting qPCR amplicons were also sequenced to confirm their identity. For each tissue, two to four endogenous controls were tested and the best individual or combination of endogenous control was chosen using NormFinder. Therefore, Ribosomal protein L32 (RPL32) and Ribosomal protein S18 (RPS18) were used as endogenous controls (Table 1) to correct for RNA extraction and reverse-transcription efficiency in the adipose tissues (SAT, TVAF, and PAT, respectively). The endogenous controls were also tested for any treatment effect and were found to be stable among samples within each tissue type, confirming their usefulness as suitable endogenous controls. Sequence-specific products were identified by generating a melting curve in which the Cycle Threshold (CT) value represented the cycle number at which a fluorescent signal

was statistically greater than the background. The relative mRNA expression was quantified using the  $2^{-\Delta\Delta Ct}$  method and thereby the fold change was calculated (**Supplementary Tables**).

# Quantitative RT-PCR Analysis for MicroRNA

Total RNA from each adipose tissue was extracted from less than 100 mg of adipose tissue using the miRNeasy Kit (Qiagen, Germantown, MD, USA), in accordance with the manufacturer's instructions. Following that, all total RNA samples were quantified using a spectrophotometer (ND-1000; NanoDrop, Wilmington, DE, USA). The purity of RNA (A<sub>260</sub>/ A<sub>280</sub>) for all samples was above 1.9, and total RNA from each individual calf and tissue was reverse-transcribed with Mir-X miRNA First-Strand Synthesis Kit (Takara Bio USA, Inc.), in accordance with the manufacturer's instructions. Briefly, cDNAs were reverse-transcribed from 100 ng of total RNA using 2× mRQ buffer and mRQ enzyme miRNA assay. This was performed in a thermal cycler, in which the tube was incubated for 1 h at 37°C, followed by termination at 85°C for 5 min to inactivate the enzymes. After that, 90 µl of ddH<sub>2</sub>O was added to bring the total volume to 100 µl. Next, the reversetranscription product was amplified with TB Green qRT-PCR miRNA assay, in accordance with the manufacturer's instructions, while fluorescence signal was detected with a Plus-one Real-time PCR System Detector<sup>®</sup> (Applied Biosystems). U6 snRNA was selected as reference miRNA in this study due to its stable expression among all animals and treatments. In the current study, the expression of miRNAs (miR-15b, 16b, 19b, 27b, 33a, 101, 130a, 148a, 152, 196a, 204, 296-3p, and 378) was analyzed (Table 2). The relative quantification of miRNA (or miR) was performed using the  $2^{-\Delta\Delta CT}$  method (Supplementary Tables).

## **Statistical Analysis**

Data were analyzed as a randomized complete block design with cow as the experimental unit. The fixed effect was maternal treatment and the random effect included maternal farm of origin. Data were analyzed using SAS (Version 9.2, SAS Institute, Inc. Carey, NC, USA) and treatment means were compared using the PDIFF option. Expression differences of mRNA and microRNA between three kinds of adipose tissue depots (SAT, TVAT, and PAT) were determined using Dunnett's modified Tukey-Kramer pairwise multiple comparison test (DTK). Differences were considered significant at p < 0.05 and trends were considered at 0.05 .

## RESULTS

## Phenotypic Data

The fetuses obtained in this experiment at slaughter (day  $260 \pm 8.3$ ) showed marked differences between the LOW and HIGH groups, as reported by Zhang et al. (35; **Table 3**). The body, carcass muscle, carcass adipose tissue, and carcass bone weights of LOW fetuses were lower than those of HIGH

Percessione proliferator activated mesptor gamma $PPARG$ RevFindACCACCGTTGACTTCCCCG ACCACGCTCCACTTGATTGC ACCAGCCTCCACTTGATTGC NL_176764.2137CCAAT/enhancer-binding protein sights $CEPR$ FW $CCAACCTATGCAAGGACCTCCCCTTGGCFWNL_176764.2109Steeroyl-CoA desaturasefaity acid synthaseSCDFWCCACCTAACGCAGGCAGGCCCTACCACGCCGCAGGCAGGCCCACCCTAACGCAGGCAGGCCTCACCACGCCAAGGCAGGCCCTACCAAGGCACGTCTNL_173869.4195Eastfaity acid synthaseFABPFWFWCCACGTATTCACCAGCACGAGCCACCTTGACCACCCAAGGCAGGTCTGACCACCCACACGCAGGCAGTCNL_173865.4NL_17414235EastLeptinEPRFWFWACAGGAAGGTATCCACACGGAGTCTGACATCTCACACACGGAGTCTACACGTATCCACCACGGAGTGTGRWNL_173865.3114Tumon Necrosis Factor \alphaTNF\alphaFWFWAACGAGGAGCCCCATGGAARWNL_173865.2180Uncoupling protein 1UCP7FWFWAACGAGGAGCTGCTGACCARWNL1016528.1220PRAG coactivator 1 \alphaPRC/TAFWCCCTTCCCCGTGGGCAGTGGAARWNL101675185.2152PRAG coactivator 1 \alphaPRC/TAFWCGCAGGGCATGTGAACFWNL173867.3216Insulin-like growth factor 1IGF1FWCGCAGGGCATGTGACCFWNLNL174667.2Insulin-like growth factor 1 receptorIGF2FWCGCAGGGAGTTGGTGTGGFWNLNL174667.2Insulin-like growth factor 2 receptorIGF2FWCGCAGGGAGTTGGGGGGGCFWNL174667.2199Insu$		Gene		Sequence 5'-3'	GenBank Accesion	Product Size (bp)
Bay     ACAGECTCACTTTGATTGC     NM_176784.2     109       CACAT/reinhander-binding protein alpha     SCD     Fwd     CCTGACCAGGAGACTCTCG     NM_173969.4     195       Stearyl-CoA dissturase (delta-9-desaturase)     SCD     Fwd     CCACCTAGGAGAGCCCAC     NM_01012869.1     226       Falty acid synthase     FAS     Fwd     GCAGCTAGTCAGCAGGCAGCT     NM_01012869.1     226       Falty acid binding protein 4     FABP4     Fwd     GCAGCTAGTCAGAGGCAGCT     NM_01080448.3.3     11       Leptin     LEP     Fwd     TGAGCAGCTAGTCAGCAGGCAGTC     NM_01080448.3.3     14       Tumor Necrosis Factor α     TN/Fα     Fwd     ACAGGAGAGGCCCTCTGGGCCAT     NM_0101869.1     226       Uncoupling protein 1     LCP1     Fwd     TGCAGCTCTCACCCTCGGGCGTCTAACCA     NM_0016528.1     216       Uncoupling protein 1     LCP1     Fwd     CACGTGCATCCACCTCGTGGCCAA     NM_0016528.1     216       PFASET Domain 16     PCML/F6     Fwd     CCAGTGCACCTCACCTCAACA     NM_001101893.1     216       Insulin-like growth factor 1     GFF7     Fwd     CAGGTGCGTCCACCCTCA     NM_001010	Peroxisome proliferator-activated receptor gamma	PPARG	Fwd	ACCACCGTTGACTTCTCCAG	NM_181024.2	137
CCAAT/onhancer-binding protein alpha CEBPA Fwo GCTGACCAGTGACAGTCACC NM_178794.2 109   Brav CGACCATTACACAGTCACC NM_17898.4 195   Stearoyl-CoA desaturase (delta-9-desaturase) SCD Fwv CGACCATTACACAGCAGGAGAGTC NM_0101269.1 226   Fatty acid synthase FASN Fwv CTACCAAGCCAGGCAGATC NM_174314 235   Fatty acid bunding protein 4 FABP4 Fwv CGACACATTATACCAGCAGGCAGTC NM_174314 235   Leptin LEP Fwv TGACAAGTCATCACAGCAGAGTCG NM_173966.3/ XM_027524120.1 180   Leptin LEP Fwv GCACACATTATACCAGCAGGAGTCG NM_173966.3/ XM_027524120.1 180   Uncoupling protein 1 LCP7 Fwv GACGAGCATTATACCAGCGGGA NM_01166528.1 220   Uncoupling protein 10 LCP7 Fwv GACGAGCATTATACACAC NM_001166528.1 220   PPAPEG coactivator 1 α PGD/16 Fwv CACGTGGGCAGGTGTACACA NM_0101168528.1 216   PPAPEG coactivator 1 42 CAGGTAGGCATTGGTCGACA CCTTCCAGGGTGGTGATAGA NM_001101883.1 216   Tind finger protein 423 CFPA2 Fwv CCCCAGCGTGGGCATACACA NM_010101883.1 216   Tind finger protein 423 CFPA Fwv <td< td=""><td></td><td></td><td>Rev</td><td>ACAGGCTCCACTTTGATTGC</td><td></td><td></td></td<>			Rev	ACAGGCTCCACTTTGATTGC		
Ber     CTTACCAGGGGGGGTGTCG     W       GCAGCCAGACGAGCCGAGCA     ML173859.4     195       Falty acid synthase     FASN     Fwor     GCAGCCTAGAGCGGAGCAGTC     ML01012669.1     226       Falty acid synthase     FASP     Fwor     GCACCTAGACGAGGCAGTC     ML01012669.1     226       Falty acid binding protein 4     FASP     Fwor     GCACCTAGACAGCGAGTC     ML174314     235       Leptin     LEP     Fwor     TGGACATCGACACGAGCAGTC     ML0101806453.3     114       Tumor Necrosis Factor α     TNFα     Fwor     ACGGGTAGGCAGTGG     ML011608245.1     220       Unocuping protein 1     U/OP1     Fwor     ACGGTGGGCAGCTGAAX     ML00116652.1     220       PRSET Domain 16     PRDMT6     Fwor     CCACGTGGGGGGGTGTAAX     ML00116653.1     216       PPARS coachiver 1     GCGT     Fwor     TGCAGGTGCAGTGAC     ML017346.3     95       Tinsulin-like growth factor 1     GFGT     Fwor     CCAGGTGGGCAGGGGGTGTGAT     ML001077828     141       Insulin-like growth factor 1     GFGT     Fwor     CCAGGTGGCACTACGCACGTGA     M	CCAAT/enhancer-binding protein alpha	CEBPA	Fwd	GCTGACCAGTGACAATGACC	NM_176784.2	109
Stearoy-CoA desturase (delta-9-desaturase)     SCD     Fwd     CGACCCTARGACCC     MM, 173959.4     195       Faity acid synthase     FASN     Fwd     CTACCCATCTACGACGCCAGGTC     MM, 010102669.1     226       Faity acid binding protein 4     FABP4     Fwd     CGACGCATCTACTGGCAGGTC     MM, 173969.4     226       Lepin     LEP     Fwd     GGACGCATCTACGCACAGG     MM, 173969.4     236       Lepin     LEP     Fwd     TGACATCTCACACACGCGCAGT     XM, 010804453.3     114       Tumor Necrosis Factor α     TWFα     Fwd     GACGTGCTACTCCGGGAGT     XM, 010804453.3     114       Tumor Necrosis Factor α     TWFα     Fwd     GACGTGCTACTCCGGGAGT     XM, 01160528.1     220       PR/SEDDmain 16     UCPT     Fwd     GCACTGCTACTACCT     XM, 015475185.2     162       PPARG coactivator 1 α     PGF1 ar     Fwd     CGACGGCATGTACTACAC     VM, 010101833.1     216       Finalin-like growth factor 1     IGF1 Fwd     GATCCTCTCAGCTCTCACTAC     NM, 01077828     141       Insulin-like growth factor 2 receptor     IGF2 Fwd     CGACGGCTGTACCACGGAGT     NM, 170867.2<			Rev	CTTGACCAGGGAGCTCTCG		
Bev     GCAGCACTATTCACCAGCAGCA     W     W     OTACCAGCAGCAGCAGCA     M     001012669.1     226       Fatty acid binding protein 4     FABP4     Fwd     GCACATTGTACTGGGCATCG     M     M     011012669.1     226       Fatty acid binding protein 4     FABP4     Fwd     TGGACAACGTATCCAGCAGCA     M     114       Laptin     Lep     Fwd     TGGACAACGTATCCAGCAGCA     M     114       Tumor Necrosis Factor α     TNFα     Fwd     ATGCCCATCTCCCTCGGGG     M     114       Uncoupling protein 1     UCP1     Fwd     ATGCCACATTCCCCGGGGAGCTGAA     M     100080453.3     114       Uncoupling protein 1     UCP1     Fwd     AAACGAAAGGGCCATGAA     M     1001166528.1     220       PR/SET Domain 16     PRDM16     Fwd     CACAGTGGGGGGGGGTGGTAACTACCT     M     0117945.3     95       Zinc finger protein 423     ZPP23     Fwd     CGCAGGTGGTGTA     M     01011993.1     216       Insulin-like growth factor 1     GF1F     Fwd     CGCAGGCAGTGGTG     M     001017928.8     114	Stearoyl-CoA desaturase (delta-9-desaturase)	SCD	Fwd	CGACCTAAGAGCCGAGAAGC	NM_173959.4	195
Fatty acid synthase FASN Fwd CTACCAAGCCAGCC MU_001012869.1 226   Petty acid binding protein 4 FAB Fwd ACAGGAAGCTCATCCTGGCCAGCA 235   Laptin LEP Fwd ACAGGAAGCTCACAGGCAGGC MU_01012869.1 236   Laptin LEP Fwd ACGCCATCCCACAGCAGGC MU_010804453.3 114   Tumor Necrosis Factor α TNFα Fwd ACGCCATCCCACAGGCAGGC MM_011166528.1 220   Uncoupling protein 1 UCPT Fwd CACGCGGGCTCTACCCACA MU_01166528.1 220   PPSET Domain 16 PPLMIF Fwd CACGCGGGCTCTACCCACA MU_01166528.1 220   PPSET Domain 16 CPCT a Fwd CACGCGGGCCTTACCACACA MU_01166528.1 220   PPSET Domain 16 CPCT a Fwd CCCACGGGCCTTACCACACA MU_01166528.1 216   Tins lin-like growth factor 1 GPCT a Fwd CCCACGGGCCTTACCACA MU_0117945.3 95   Tinsulin-like growth factor 1 GPT a Fwd CACGCACGGCAGGTC MU_01101893.1 216   Insulin-like growth factor 2 receptor GPT a Fwd CACGCACGCAGGCACACA MU_01101893.1 216   Insulin-like growth factor 2 receptor GPT a Fwd CACGCACGCCTCCCCACA			Rev	GCAGCACTATTCACCAGCCAG		
Felty acid binding protein 4     NM_174314     235       Laptin     LeP     Fed     Fod     Fod CAGGGAAGGTC CAGGAGTC     XM_010804453.3     114       Tumor Neorosis Factor α     TNF α     Fed     AGCGGCTCTCCCCTCROGG     NM_173968.3/ XM_027524120.1     180       Uncoupling protein 1     UCP 1     Fed     AACGGAAGGGCCAGGGG     NM_00116528.1     220       Uncoupling protein 1     UCP 1     Fed     AACGGAAGGGCCAGGGGGGGGGGGGGGGGGGGGGGGGG	Fatty acid synthase	FASN	Fwd	CTACCAAGCCAGGCAGGTC	NM_001012669.1	226
Fatty acid binding protein 4   FABP Fewd   FABP Fewd   FABPA FEWDA			Rev	GCCATTGTACTTGGGCTTGT		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Fatty acid binding protein 4	FABP4	Fwd	ACAGGAAAGTCAAGAGCATCGT	NM_174314	235
Leptin     LEP     Fvd     TGACATCTCACACGCAGTCC     XM_010804453.3     114       Tumor Necrosis Factor α     TNFα     Fvd     AAGCATGATCGCAGTGCAT     XM_010804453.3     114       Tumor Necrosis Factor α     TNFα     Fvd     AAGCATGATCCAGGGAATGTGG     NM_173966.3/ XM_027524120.1     180       Uncoupling protein 1     UCP1     Fvd     AAACAAGAGGGCCAGTGAAA     NM_01166528.1     220       PP/SET Domain 16     PRD/M16     Fev     TGCAGTCTGACCACTCACCAG     NM_177945.3     95       PPAG coactivator 1 α     PGC1α     Fvd     GCGATGTGACCATCAGAGGCAGCAGTA     NM_011101893.1     216       Insulin-like growth factor 1     IGF1     Fvd     GCGATGTCACACAGGGAGAGGTATCAC     NM_001101893.1     216       Insulin-like growth factor 1 receptor     IGF1     Fvd     GCATGCTCATCAGATCAC     NM_001077828     141       Insulin-like growth factor 2 receptor     IGF2     Fvd     CCAGCGAGTATGCCCAGGGCAGTACC     NM_001244612     139       Insulin-like growth factor 2 receptor     IGF2     Fvd     GCAGCGTATGTAGCACCAGGAGGACCA     NM_174087.3     95       Insulin-receptor substrate 1			Rev	TGGACAACGTATCCAGCAGA		
Fer Tumor Necrosis Factor $\alpha$ TNF $\alpha$ NP Part of CAGTGATCGAGCATGTGG Part of CAGTGATCGAGCAGTGTGG Part CAGTGATCACGAGCAGTGTAGNM_173966.3/ XM_027524120.1180Uncoupling protein 1UCP1 Part of CAGTGATCGAGCAGTGTGG PARSET Domain 16UCP1 Part of CAGTGGCAGTGTGACTGACCACNM_001166528.1220PPA/SET Domain 16PB/M16FwdCCTTCCCGGGGCAGTGTGACCACXM_015475185.2152PPARG coactivator 1 $\alpha$ PGC1 $\alpha$ Part of CGGGCAGTGTGTGATAGNM_001101893.1216PPARG coactivator 1 $\alpha$ PGC1 $\alpha$ Part of CGGGCAGTTGGTTGAACACNM_001101893.1216Insulin-like growth factor 1IGF1 Part of CCCAGGAGATTGGTGGGAGCGCACCANM_001017828141Insulin-like growth factor 1IGF2 Part of CCCAGGCAGCACACANM_001244612139Insulin-like growth factor 2 receptorIGF2R Part of CCAGGCAGCAACCAGGGGGTCNM_001244612188Insulin-like growth factor 2 receptorIGF2R Part of CCAGCGATAGCGAGCACANM_001244612188Insulin-like growth factor 2 receptorIGF2R Part of CCAGCGATGGTGGTGTGTGTG Part of CCAGCCTAGTGGGCAGGGCCNM_174087.3287Insulin-like growth factor 2 receptorIGF2R Part of CCAGCAGCTAGCTGCACCTXM_002688822114Insulin-like growth factor 2 receptorIGF2R Part of CCACCGGGGGGCCNM_174087.3287Insulin-like growth factor 2 receptorIGF2R Part of CCACCGCAGCTAGCCGAGCGGGCCNM_174087.3287Insulin-like growth factor 2 receptorIGF2R Part of CCACCGGCAGCTAGCCCGAGCGGGCCNM_174087.3287Insulin-like growth fact	Leptin	LEP	Fwd	TGACATCTCACACGCAGTC	XM_010804453.3	114
Tumor Necrosis Factor $\alpha$ TNF $\alpha$ FwdAdGCATGATCOGGGATGTGG FWdNM_173966.3/XM_027524120.1180Uncoupling protein 1UCP1FwdAAACAGAAGGGCCAGTGAAANM_001166528.1220PR/SET Domain 16PRDM16FwdCGTCCCGGGTCOTCACTAXM_015475185.2152PPARG coactivator 1 $\alpha$ PGC $\alpha$ FwdTGCAGTGGAAAGTGGCCAGGTGTGATAGNM_177945.395PPARG coactivator 1 $\alpha$ PGC $\alpha$ FwdTGCAGTGGAAAGTTGGTGGTGGTAGNM_001101893.1216Insulin-like growth factor 1IGF1FwdGCGTCGGTGAAAGTTGGTGGTNM_001017828141Insulin-like growth factor 2 receptorIGF2RFwdCCAAGGCAATGTGGGGGGGTCNM_001244612139Insulin-like growth factor 2 receptorIGF2RFwdCCAAGGCAATGTGGGGGGGTCNM_174087.395Insulin-like growth factor 2 receptorIGF2RFwdCCAAGGCAATGTGGGGGGGTCNM_174087.395Insulin-like growth factor 2 receptorIGF2RFwdCCAGGAAGGACAGGAAGGCAAGGGGGGTCNM_174087.395Insulin-like growth factor 2 receptorIGF2RFwdCCAGGAAGGACAGGGAAGGGGGGTCNM_174087.395Insulin receptor substrate 1INSRFwdCCATGCCCTAGGTGTGACCTNM_002888577.3.5287Prosphoinositide-3-kinasePI3K/R2FwdCCATGGCGCAGCAAGGGGGGGGGNM_173986.2141Insulin receptor substrate 1IRS1FwdCCAGGAGGAGGCAGGAGGGGGGGNM_174576.299Prosphoinositide-3-kinase 2AXTFwdCCAGGGAGGGGGGGGGGGGGGGGGG			Rev	ATCGCCAATGTCTGGTCCAT		
$\begin{tabular}{ c c c c c } & Periode Control Contr$	Tumor Necrosis Factor α	$TNF\alpha$	Fwd	AAGCATGATCCGGGATGTGG	NM_173966.3/ XM_027524120.1	180
Uncoupling protein 1 UCP1 Fwd AAACAGAAGGGCCAGTGAAA NM_001166528.1 220   PR/SET Domain 16 PRDM16 Fwd CCTCCCCGGTCTACCTA XM_015475185.2 152   PPARG coactivator 1 α PGC1 a Fwd CGCCAGGCAGTGTGATAG NM_01101893.1 216   PPARG coactivator 1 α PGC1 a Fwd CGCCAGGCAGTTGGATGGTGTGTAC NM_001101893.1 216   Insulin-like growth factor 1 GF1 Fwd CGCCAGGCAGTTGGATGGT NM_001077828 141   Insulin-like growth factor 2 receptor IGF1 Fwd CGACGCATTGGACGCC NM_001244612 139   Insulin-like growth factor 2 receptor IGF2 Fwd CAGGCAGTTGGACGCC NM_174387.3 95   Insulin-like growth factor 2 receptor IGF2 Fwd CAGGCAGTTGGACGCC NM_174387.3 95   Insulin-like growth factor 2 receptor IGF2 Fwd CGCAGGCAGTGGACGCC NM_174352 188   Insulin receptor substrate 1 INSR Fwd CGCAGGCAGCGAGCGAGGGGGGGTC NM_0012684832 114   Insulin receptor substrate 1 IRSF1 Fwd CGGCATGCAGCGGGGGGGTC NM_174352 287   Protein kinase B A A TGGCAGGAGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGG			Rev	GACTGCTCTTCCCTCTGGGG		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Uncoupling protein 1	UCP1	Fwd	AAACAGAAGGGCCAGTGAAA	NM_001166528.1	220
PR/SET Domain 16   PRDM16   Fwd   CCTTCCCGGGTCCTTACTA   XM_015475185.2   152     PPARG coactivator 1 α   PGC1a   Fwd   TGCAGGGGGGGGTGTGATAG   NM_177945.3   95     Zinc finger protein 423   ZFF423   Fwd   GCGTCGGTGAAAGTTGAAAGTTGAAAGTGAAAGTTGAAGTG   NM_001101893.1   216     Insulin-like growth factor 1   IGF1   Fwd   GATGGTCTCCCAGGTCGTGG   NM_001077828   141     Insulin-like growth factor 2 receptor   IGF1   Fwd   CAAGGCAACTCTGCTCAAGTCAC   NM_001244612   139     Insulin-like growth factor 2 receptor   IGF2   Fwd   CCAGGCAATTGGAAGCTTCAC   NM_174087.3   95     Insulin-like growth factor 2 receptor   IGF2   Fwd   CCAGCAATTGGAAGGGCC   NM_174087.3   95     Insulin-like growth factor 2 receptor   IGF2   Fwd   CCAGCATGCTAAGGGCCGC   NM_174087.3   95     Insulin-like growth factor 2 receptor   IGF2   Fwd   CCAGCATGCTACACCCGGAAGTGTATGC   NM_002688832   114     Insulin-like growth factor 2 receptor   IGF2   Fwd   CGTGCTCGTGGTGTCTCGCTT   XM_002688832   114     Insulin-like growth factor 2 receptor   IGF2   Fwd   CGTGCCTGGTG			Rev	TGCAGTCTGACCTTGACCAC		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	PR/SET Domain 16	PRDM16	Fwd	CCTTCCCGGGTCCTTACCTA	XM_015475185.2	152
PPARG coactivator 1 $\alpha$ PGC1 $\alpha$ FwdTGCAGTTACACATCACCACTCACCTCANM_177945.395Zinc finger protein 423ZPP423FwdCGCTCGTGAAAGTTGGAGGGGTNM_001101693.1216Insulin-like growth factor 1IGF1FwdCGCACGGTCATCACAGTTGGTGGGGNM_001077828111Insulin-like growth factor 1 receptorIGF1FwdCCACGCCTCCTCACAGTCCNM_001244612139Insulin-like growth factor 2 receptorIGF2FwdCCAGGAAGGAAAGGAACCANM_174087.395Insulin-like growth factor 2 receptorIGF2FwdCCAGCACTATGGGCGCGGTCNM_174087.395Insulin-like growth factor 2 receptorIGF2FwdCCAGCACTATGGGGCGGGTCNM_174087.395Insulin-like growth factor 2 receptorIGF2FwdCCAGCACTATGCCCTGGTGTCACTTXM_002688832114Insulin-like growth factor 2 receptorISF1FwdCGAATGCCACCAGCAGAAGGAAXM_003585773.5287Insulin receptor substrate 1INSRFwdTGGAACACCACACACACACACAXM_003585773.5287Protein kinase BAKT1FwdTGGAAGACTTCTGGCGGGACCNM_174576.299RevCTGGGTGTGACACACACACACACACACACACACACACACA			Rev	CAGGTGGGCAGGTGTGATAG		
RevTGCCAGGAGTTGGATZinc finger protein 423 $ZFP423$ FwdCGCCAGGAAGTTGAAAGTNM_001101893.1216RevCTGACAGTGATCGCAGGTGTNM_001077828141Insulin-like growth factor 1InceptorIGF1FwdGATGCTCCCAGGTCGTCAGTCACNM_001244612139Insulin-like growth factor 2 receptorIGF2FwdCAAGGCAACTGGGGGGGGGTCNM_174087.395Insulin-like growth factor 2 receptorIGF2FwdCCAGCAATTGGAGGGGGGGTCNM_174087.395Insulin-like growth factor 2 receptorIGF2RFwdGCAATGCTAAGGTTGGAACCNM_174352188Insulin-like growth factor 2 receptorIGF2RFwdGCAATGCTAAGGTTGGAACCNM_002688832114Insulin-receptorINSRFwdCCTAGCCTAGGTGCACTTXM_002688832114Insulin receptorINSRFwdGGGCATACACAGCAGAATGAAGAXM_003585773.5287Phosphoinositide-3-kinaseIRSIFwdGGGGCGTTGCGCGACAAAGGAATGAACGAXM_003585773.5287Protein kinase BAKT1FwdTGAAGACTTCTTCGCGACACAAAGGAATGAACGANM_174576.299RevCCTGGTGTGAAGGGCACACAAAGGNM_174576.299114RevCCTGGCGGGGGCGTCTTGGCACACAAAGGGANM_001206146.1148Glucose transporter 4AKT2FwdCCTGGCAGCAACAAGGGGNM_001206146.1148RevAGCCTGCTCATGTCCTCGTGGTRevAGCCAGCCTGCTTGTCGTGGTGNM_001033614.2174Glucose transporter 4GLUT4FwdCCTCCGACTCGACTCA </td <td>PPARG coactivator 1 <math>\alpha</math></td> <td>PGC1α</td> <td>Fwd</td> <td>TGCAGTACACATCAGCCTCA</td> <td>NM_177945.3</td> <td>95</td>	PPARG coactivator 1 $\alpha$	PGC1α	Fwd	TGCAGTACACATCAGCCTCA	NM_177945.3	95
Zinc finger protein 423 ZFP423 Fwd CGCTCGGTGAAAGGAA NM_001101893.1 216   Insulin-like growth factor 1 IGF1 Fwd CGACAGTGATCGCAGGTGT NM_001077828 141   Insulin-like growth factor 1 receptor IGF1R Fwd CAAAGGCAATCGCCCTCTCAGATCAC NM_001244612 139   Insulin-like growth factor 2 receptor IGF2 Fwd CCAGCAGGACAAGGACACG NM_174087.3 95   Insulin-like growth factor 2 receptor IGF2 Fwd CCAGCAGGACAGGAGCA NM_174352 188   Insulin-like growth factor 2 receptor IGF2R Fwd CCATGTCCAGGTTCAGCT NM_0020268832 141   Insulin-like growth factor 2 receptor IGF2R Fwd CCATGTCCAGCGGGTC NM_174352 188   Insulin-like growth factor 2 receptor IGF2R Fwd CCATGTCCAGCTGCAGTT XM_002688832 141   Insulin-like growth factor 2 receptor IGF2R Fwd CGGCACTCAAGCAGGAGAATGAGAC XM_002688832 141   Insulin-like growth factor 2 receptor IGF2R Fwd CGGCACTCACAGCAGAGAAGGAGAATGAGA XM_002688832 141   Insulin-like growth factor 2 receptor INSR Fwd CGGCACTCACAGCAGGAGAATGTGCAC XM_002688832 141   Insulin-like growth factor 2 receptor INSR Fwd			Rev	TGCCAGGAGTTTGGTTGTGAT		
RevCTGACAGTGATOGCAGGTGT RevNM_00107828141Insulin-like growth factor 1 <i>IGF1</i> FwdGATGCTCTCCAGTTCGTGTG CTCCAGCTCCTCAGATCANM_001244612139Insulin-like growth factor 2 receptor <i>IGF2</i> FwdCCAGGAGGAGAGCA RevAGACCTAGTGGGGCGGTCNM_174087.395Insulin-like growth factor 2 receptor <i>IGF2</i> FwdCCAGCGATTAGAAGTGAGCCNM_174087.3188Insulin-like growth factor 2 receptor <i>IGF2</i> FwdCCAGCGATTAGCAGGGCGGTCNM_174087.3188Insulin-like growth factor 2 receptor <i>IGF2</i> FwdCCATGCCACCGGAGGTGTATTXM_002688832114Insulin receptor <i>INSR</i> FwdCCTGCCTTAGGTTCGACTTXM_003555773.5287Insulin receptor substrate 1 <i>IRS1</i> FwdTGGACATCACAGCAGAATGAAGACNM_174576.299Protein kinase B <i>AKT1</i> FwdAACCGAGGAAGCGAACGGGACCACAGAGGNM_174576.299 <i>Rev</i> AGCCAGCTCTTAGTGTAGCCACACAAGGGNM_174576.29914Act serine/threonine kinase 2 <i>AKT2</i> FwdACCGAGGAAGGAGAAAGGGAACACAGGGNM_174576.299Akt serine/threonine kinase 2 <i>AKT2</i> FwdACGAGGAAGGAGAAGAGGACAAAGGGANM_0010206146.1148RevAGGCCTCCAACGAGGCACACAAGGGNM_0010206146.1148148RevAGGTCCTCAAGGACCACCCTCTGGTGACXM_002694043.6285Akt serine/threonine kinase 2 <i>AKT2</i> FwdCCTGCAACAGGTCCATCGTGTGTNM_174604.1146RevAGGTCCTCAAGGACACGCCTCTGGTGGCNM_001033614.	Zinc finger protein 423	ZFP423	Fwd	CGCTCGGTGAAAGTTGAAGA	NM_001101893.1	216
Insulin-like growth factor 1   IGF1   Fwd   GATGCTCTCCAGTGGTTGG   NM_001077828   141     Insulin-like growth factor 1 receptor   IGF1R   Fwd   CAAGGCAATCTGCTCATCA   NM_001244612   139     Insulin-like growth factor 2 receptor   IGF2   Fwd   CCAAGGCAATCTGCTCATCA   NM_174087.3   95     Insulin-like growth factor 2 receptor   IGF2   Fwd   CCAGCCATTGTGGGGCGGGTC   NM_174352   188     Insulin-like growth factor 2 receptor   IGF2R   Fwd   GCAATGCTAGCGGAAGTGAAGCA   NM_00388573.5   287     Insulin-receptor   IMSR   Fwd   CGTGCTTAGGCACGCAAGGAAGAGAGA   XM_003585773.5   287     Insulin receptor substrate 1   IRS1   Fwd   TGGACACACAGCAGCAAGGAAGTGAAGCA   XM_003585773.5   287     Phosphoinositide-3-kinase   PI3K(R2)   Fwd   TGGACGCACAGCAGCAAGGGA   NM_17456.2   99     Rev   TCGAGGGGAGGCACACACAGGG   NM_17456.2   97   98   141   141     Mechanistic target of rapamycin kinase   AKT2   Fwd   ACGCAGCACACACAGGGCACACACAGGGCA   NM_001206146.1   148     Glucose transporter 4   GLUT4   Fwd   GCTCCCAAGCAGCTCTCTTGGTGG			Rev	CTGACAGTGATCGCAGGTGT		
RevCTCCAGCCTCCTCAGATCACVInsulin-like growth factor 1 receptor $IGF1R$ FwdCAAAGGCAAATCGAGACCANM_001244612139Insulin-like growth factor 2 receptor $IGF2$ FwdCCAGCGATTAGAAGTGAGCCNM_174087.395Insulin-like growth factor 2 receptor $IGF2R$ FwdGCACTCAGTGGGCGGTCNM_174087.395Insulin-like growth factor 2 receptor $IGF2R$ FwdGCAATGCTAAGGCTTTCGTATTACGNM_174352188Insulin-like growth factor 2 receptor $IGF2R$ FwdGCATGCCCTGGTGTCACTTXM_002688832114Insulin receptor substrate 1 $INSR$ FwdCCTATGCCCTGGGTGTCACTTXM_003585773.5287Insulin receptor substrate 1 $IRS1$ FwdGGAACGCAAGCAAGGAAGCGANM_174576.299Protein kinase B $AKT1$ FwdTGAAGCTTTCTGCGGGACCNM_173986.2141RevCCTGGTTGTAGAAGGCAAGCAAGCGACACAAGGANM_001206146.1148RevAGCCAGCCATCTTGGACATCXM_002694043.6285Rethanistic target of rapamycin kinase $mT0R1$ FwdGCTTCCAACAAGCAGCTGCXM_002694043.6285Glucose transporter 4 $GLU74$ FwdGCTTCCAACAAGCAGCTGCTCGGAANM_00103614.2178Reference genes $RPS18$ FwdGCCACGCTCCATGCTCGCACCANM_00103614.2178RevGCCACGTCTCTGGCACCCT $MO_001034783.2$ 169RevGCCACGTCTCTGGCACCCT	Insulin-like growth factor 1	IGF1	Fwd	GATGCTCTCCAGTTCGTGTG	NM_001077828	141
Insulin-like growth factor 1 receptor   IGF1R   Fwd   CAAGGCAATCTGCTCATCA   NM_001244612   139     Insulin-like growth factor 2 receptor   IGF2   Fwd   CCAGCAAGGACAAGGACACG   NM_174087.3   95     Insulin-like growth factor 2 receptor   IGF2R   Fwd   GCAGTTAGAAGTGAGCC   NM_174087.3   95     Insulin-like growth factor 2 receptor   IGF2R   Fwd   GCAGTTACCACGGAAGTTGTATC   NM_174352   188     Insulin-like growth factor 2 receptor   IGF2R   Fwd   GCAGTGACCGAGAAGTGAAGC   NM_002688832   114     Insulin receptor   INSR   Fwd   CCTATGCCTTGGTGTCACTT   XM_002688832   114     Insulin receptor substrate 1   IRS1   Fwd   TGGACATCACAGCAGCTAATGCACT   XM_002688832   287     Insulin receptor substrate 1   IRS1   Fwd   TGGACATCACAGCAGCTAAGTCCACT   XM_002688632   114     Insulin receptor substrate 1   IRS1   Fwd   TGGACATCACAGCAGCAAGCGA   XM_002688832   114     Insulin-like growth factor 2 receptor   IRS1   Fwd   TGGACATCACAGCAGCAAGCGA   NM_00103685773.5   287     Insulin-like growth factor 2 receptor   IRS1   Fwd   TGGACACGGACGACC			Rev	CTCCAGCCTCCTCAGATCAC		
RevCAGGAAGGACAAGGAGAGACCAInsulin-like growth factor 2 receptor <i>IGF2</i> FwdCCAGCGATTGAAAGGAGACCNM_174087.395Insulin-like growth factor 2 receptor <i>IGF2R</i> FwdGCAATGCTAGGGGGGCNM_174352188Insulin receptor <i>IGF2R</i> FwdCCATTGCCACCGGAAGTTGTATGNM_002688832114Insulin receptor <i>INSR</i> FwdCGAGTGACCACGGCAGCTAGTTXM_002688832114Insulin receptor substrate 1 <i>IRS1</i> FwdTGGACATCACAGCAGAATGAAGAXM_003585773.5287Phosphoinositide-3-kinase <i>P13K</i> ( <i>R2</i> )FwdACCGAGGAGCAGCAGCAGCGNM_174576.299Protein kinase B <i>AKT1</i> FwdTGAAGCATCACAGCGACCACAAGGNM_174576.2141RevCCTGGTGTGAGAGGAGCCAACCAAGGNM_173986.2141AKT serine/threonine kinase 2 <i>AKT2</i> FwdACGAGGGAGAGGAGGAGGAGG148Glucose transporter 4 <i>GLUT4</i> FwdCCTTGGCACAACAGGGCATCXM_002694043.6285Reference genes <i>RPS18</i> FwdTTCCAGCACATCTTGCGGGACCNM_174604.1174Reference genes <i>RPS18</i> FwdTTCCAGCACATCTTGCGGGATCNM_001033614.2178RevTGCACACTTCCACCTGGCACACCRevTTGCACACCTCCGGCACCNM_001034783.2169RevTTGAATTCTCTCGGGGACCFWdGCCACTCTCTCGGGCACCNM_001034783.2169	Insulin-like growth factor 1 receptor	IGF1R	Fwd	CAAAGGCAATCTGCTCATCA	NM_001244612	139
Insulin-like growth factor 2 receptor IGF2 Fwd CCAGCGATTAGAAGTGAGCC NM_174087.3 95   Insulin-like growth factor 2 receptor IGF2 Fwd GCAATGCTAAGGGGGGGGTC NM_174087.3 95   Insulin-like growth factor 2 receptor IGF2 Fwd GCAATGCTAAGCTTTCGTATTACG NM_174352 188   Insulin receptor INSR Fwd CCTATGCCCTGGTGTCACTT XM_002688832 114   Insulin receptor substrate 1 IRSI Fwd GGACATCACAGCAGAAGAGAGA XM_003585773.5 287   Phosphoinositide-3-kinase IRSI Fwd TGGACATCACAGCAGAAGTCAAGCA XM_0174576.2 99   Protein kinase B AKT1 Fwd TGAAGCTTTGTGGGGGGGCC NM_174576.2 99   AKT serine/threonine kinase 2 AKT2 Fwd TGAGCAGTTGTGGGGGGACC NM_173986.2 141   Rev AGCCAGCCTTCTTTGATGAAGGGGAAC AM_0010206146.1 148   Rev AGCCAGCCTTCTTTGATGACAG AM_0010206146.1 148   Rev AGCCAGCCTCATGCTCCTGTGGTG M_0010206146.1 148   Rev AGCCAGCCTCATGCCTCAGGCACCA AM_002694043.6 285   Glucose transporter 4 GLU74 Fwd GCTGCCACAGAGTCGACTC XM_002694043.6 285   Reference genes RPS18 <t< td=""><td></td><td></td><td>Rev</td><td>CAGGAAGGACAAGGAGACCA</td><td></td><td></td></t<>			Rev	CAGGAAGGACAAGGAGACCA		
Insulin-like growth factor 2 receptor IGF2R Fwd GCACTGCTAGCGGGGCGGTC NM_174352 188   Insulin receptor INSR Fwd GCTGTACCACCGGAAGTTGTATGA XM_002688832 114   Insulin receptor substrate 1 IRS1 Fwd CGTGGCCTAGGTGCACTT XM_003585773.5 287   Insulin receptor substrate 1 IRS1 Fwd TGGACATCACAGGAGAAGTGAAGA XM_003585773.5 287   Phosphoinositide-3-kinase PI3K(R2) Fwd ACCGAGGAGACGACAACAGCG NM_174576.2 99   Protein kinase B AKT1 Fwd TGGAGGAGCCAACAAGGG NM_174576.2 99   AKT serine/threonine kinase 2 AKT2 Fwd ACCAGGGAAGGGAGGG NM_173986.2 141   Rev CCTGGTTGTAGAGCACAAGGGA NM_001206146.1 148   Rev AGCAGCACCACAGGGAGGGAAGGGAAGGAGA NM_001206146.1 148   Rev AGCCAGCCTCTTTGTGAGACA AGCOGAGCAGGG 141   Rev AGCCAGCACAGTGCATCACAGGGAGGA NM_001206146.1 148   Rev AGCCAGCAGCAGGGAGGG 285 285   Glucose transporter 4 GLUT4 Fwd GCTTCCAACAGTGCAGCTGG XM_002694043.6 285   Reference genes RPS18 Fwd GCCAGCCAGGCTCTGTTGGGAGG NM_001033614.2 178 </td <td>Insulin-like growth factor 2 receptor</td> <td>IGF2</td> <td>Fwd</td> <td>CCAGCGATTAGAAGTGAGCC</td> <td>NM_174087.3</td> <td>95</td>	Insulin-like growth factor 2 receptor	IGF2	Fwd	CCAGCGATTAGAAGTGAGCC	NM_174087.3	95
Insulin-like growth factor 2 receptor IGF2R Fwd GCAATGCTAAGCTTTCGTATTACG NM_174352 188   Insulin receptor INSR Fwd CCTAGCTTGCCACCGGAAGTTGTATG XM_002688832 114   Insulin receptor substrate 1 IRS1 Fwd TGGACATCACAGGAGAATGAAGA XM_003585773.5 287   Insulin receptor substrate 1 IRS1 Fwd TGGACATCACAGGAGAATGAAGA XM_003585773.5 287   Phosphoinositide-3-kinase P13K(R2) Fwd ACCGAGAGATCGACAGGAGCG NM_174576.2 99   Protein kinase B AKT1 Fwd TGAAGACTTTCTGCGGACC NM_173986.2 141   Rev TGGAGGACGGACCACACACAGGG NM_173986.2 141   AKT1 serine/threonine kinase 2 AKT2 Fwd ACGAGGAAGGAGATCACACAGGACGA NM_001206146.1 148   Glucose transporter 4 GLUT4 Fwd CCTTGGCACACACAGTGCATC XM_002694043.6 285   Glucose transporter 4 GLUT4 Fwd GCTTCCAACAGGATCTGGGCTGG NM_174604.1 174   Rev CCAGCCAGGCTTCATTGTGAGC Rev CCAGCGCAGGCTGGG NM_174604.1 174   Glucose transporter 4 GLUT4 Fwd GCTCCAACAGGATCGAGGG NM_001033614.2 178   Reference genes RPS18 Fwd TCCAGCAC			Rev	AGACCTAGTGGGGCGGTC		
RevGGTGTACCACCGGAAGTTGTATGInsulin receptorINSRFwdCCTATGCCCTGGTGTCACTTXM_002688832114RevGCTGCCTTAGGTTCGGCTGCCTTAGGTTCG114Insulin receptor substrate 1IRS1FwdTGGACATCACAGCAGAAGAGAXM_003585773.5287Phosphoinositide-3-kinasePI3K(R2)FwdAACCGAGAGATCGACAAGCGNM_174576.299Protein kinase BAKT1FwdTGAAGACTTTCTGCGGGACCNM_173986.2141AKT serine/threonine kinase 2AKT2FwdAGCGAGGAGGAGGAGGAGGAGGAGGANM_001206146.1148Mechanistic target of rapamycin kinasemTOR1FwdCCTTGGCACAACAGTGCATCXM_002694043.6285Glucose transporter 4GLUT4FwdGCTTCCAACAGATCGGCTCTGNM_174604.1174Reference genesRPS18FwdTTCCAACGTCCACTTGGCAGCANM_001033614.2178RevTGCACGTTCTTGGACCACCTCATCGNM_001034783.2169RevTGAACTTCTGGCGCACCCNM_001034783.2169	Insulin-like growth factor 2 receptor	IGF2R	Fwd	GCAATGCTAAGCTTTCGTATTACG	NM_174352	188
Insulin receptor INSR Fwd CCTATGCCTGGTGTCACTT XM_002688832 114   Insulin receptor substrate 1 IRS1 Fwd TGGACATCACAGCAGAAATGAAGA XM_003585773.5 287   Insulin receptor substrate 1 IRS1 Fwd TGGACATCACAGCAGAATGAAGA XM_003585773.5 287   Phosphoinositide-3-kinase PI3K(R2) Fwd AACCGAGAGAATCGACAAGCG NM_174576.2 99   Protein kinase B AKT1 Fwd TGAAGACTTTCTGCGGGACC NM_173986.2 141   AKT serine/threonine kinase 2 AKT2 Fwd ACGAGGAAGGGGAGGG NM_001206146.1 148   Nechanistic target of rapamycin kinase mTOR1 Fwd CCTTGGCACACACAGGGCACTC XM_002694043.6 285   Glucose transporter 4 GLUT4 Fwd GCTTCCAACAGAGTCGACTC XM_001033614.2 174   Reference genes RPS18 Fwd TTCCAGCACATCTAGCT NM_001033614.2 178   Rev TGAACGTTCGACTCATCGGCACT NM_001034783.2 169			Rev	GGTGTACCACCGGAAGTTGTATG		
RevGCTGCCTTAGGTTCTGGTTGInsulin receptor substrate 1IRS1FwdTGGACATCACAGCAGAATGAAGAXM_003585773.5287Phosphoinositide-3-kinasePI3K(R2)FwdAACCGAGAGTCGACAAGCGNM_174576.299Protein kinase BAKT1FwdTGAAGACTTTCTGCGGGACCNM_173986.2141RevTTCTGAGTGAGCAGAGGGAGGNM_001206146.1148RevACCGAGGAAGGGAGGGAGGAGGAGGAGGAGGAGGAGGAGG	Insulin receptor	INSR	Fwd	CCTATGCCCTGGTGTCACTT	XM_002688832	114
Insulin receptor substrate 1   IRS1   Fwd   TGGACATCACAGCAGAATGAAGA   XM_003585773.5   287     Rev   CATGTGGCCAGCTAAGTCCT   Rev   CATGTGGCCAGCAGCGAGCG   NM_174576.2   99     Phosphoinositide-3-kinase   PI3K(R2)   Fwd   AACCGAGAGAGCGACACAAGCG   NM_173986.2   141     Protein kinase B   AKT1   Fwd   TGAAGACTTTCTGCGGGGACC   NM_001206146.1   148     Rev   CCTGGTTGTAGAAGGGCAGG   Rev   AGCCAGCCTTCTTTGATGAACGCAA   NM_001206146.1   148     Mechanistic target of rapamycin kinase   mTOR1   Fwd   CCTTGGCACAACAGTGCATC   XM_002694043.6   285     Glucose transporter 4   GLUT4   Fwd   GCTTCCAACAGATCGCGGCTCG   NM_174604.1   174     Rev   CAGGCCAGGTCCATTGTGCAGAGT   NM_001033614.2   178     Reference genes   RPS18   Fwd   TCCAGCACATCTGCAGCATC   NM_001034783.2   169     Rev   TGAATCTTCTGCGGCACCCT   TGAACGCTCCT   NM_001034783.2   169			Rev	GCTGCCTTAGGTTCTGGTTG		
RevCATGTGGCCAGCTAAGTCCTPhosphoinositide-3-kinasePI3K(R2)FwdAACCGAGAGATCGACAAGCGNM_174576.299RevTTCTGAGTGAGCCACACAGGRevTTCTGAGTGAGCCACACAGG141Protein kinase BAKT1FwdTGAAGACTTTCTGCGGGACCNM_173986.2141AKT serine/threonine kinase 2AKT2FwdACGAGGAAGGAGTAAAGCGANM_001206146.1148RevAGCCAGCCTTCTTTGATGACARevAGCCAGCCTCCTTTGATGACA285Mechanistic target of rapamycin kinasemTOR1FwdCCTTGGCACAACAGTGCATCXM_002694043.6285Glucose transporter 4GLUT4FwdGCTTCCAACAGAGTCCTGGGANM_174604.1174RevCCAGCCAGGTCTCATTGTAGGCReference genesRPS18FwdTTCCAGCACATCTTGCGAGTNM_001033614.2178RevTGAATCTTCTGCGGCATCNM_001034783.2169RevTTGAATCTTCTGCGGCACCCTNM_001034783.2169	Insulin receptor substrate 1	IRS1	Fwd	TGGACATCACAGCAGAATGAAGA	XM_003585773.5	287
Phosphoinositide-3-kinase   P/3K(R2)   Fwd   AACCGAGAGATCGACAAGGG   NM_174576.2   99     Protein kinase B   AKT1   Fwd   TGAAGACTTTCTGCGGGACC   NM_173986.2   141     AKT serine/threonine kinase 2   AKT2   Fwd   ACGAGGAAGGAGTAAAGCGA   NM_001206146.1   148     Mechanistic target of rapamycin kinase   MTOR1   Fwd   CCTTGGTCAGAACAGTGCATC   XM_002694043.6   285     Glucose transporter 4   GLUT4   Fwd   GCTTCCAACAGGGTCTCATTGTAGGA   NM_174604.1   174     Reference genes   RPS18   Fwd   TCCAGCACATCTTGCGGAGT   NM_001033614.2   178     Rev   TGCAACCTTCTTGACTCGGCACC   NM_001034783.2   169     Rev   TTGAACTTTCTGCGGCACCCCT   TTGAACTTTCTGCGGCACCCC   174			Rev	CATGTGGCCAGCTAAGTCCT		
RevTTCTGAGTGAGCCACACAAGGProtein kinase BAKT1FwdTGAAGACTTTCTGCGGGACCNM_173986.2141AKT serine/threonine kinase 2AKT2FwdACGAGGAAGGAGTAAAGCGANM_001206146.1148RevAGCCAGCCTTCTTTGATGACARevAGCCAGCCTTCTTTGATGACA285Mechanistic target of rapamycin kinasemTOR1FwdCCTTGGCACAACAGTGCATCXM_002694043.6285Glucose transporter 4GLUT4FwdGCTTCCAACAGAGTCCTCGTGANM_174604.1174Reference genesRPS18FwdTTCCAGCACATCTTGCAGGTNM_001033614.2178RevTCACACGTTCCACTCATCGCGCATCNM_001034783.2169RevTTGAATCTTCTGCGCACCCTNM_001034783.2169	Phosphoinositide-3-kinase	PI3K(R2)	Fwd	AACCGAGAGATCGACAAGCG	NM_174576.2	99
Protein kinase B   AKT1   Fwd   TGAAGACTTTCTGCGGGACC   NM_173986.2   141     Rev   CCTGGTTGTAGAAGGGCAGG   NM_001206146.1   148     AKT serine/threonine kinase 2   AKT2   Fwd   ACGAGGCAGGCCTTCTTTGATGACAGCGA   NM_001206146.1   148     Mechanistic target of rapamycin kinase   mTOR1   Fwd   CCTTGGCACAACAGTGCATC   XM_002694043.6   285     Glucose transporter 4   GLUT4   Fwd   GCTTCCAACAGAGTCCTCGTGA   NM_174604.1   174     Reference genes   RPS18   Fwd   TCCAGCAACATCTTGCGGGAGT   NM_001033614.2   178     Rev   TCACACGTTCCACTCGGCACC   NM_001034783.2   169     Rev   TTGAATCTTCTGCGCACCCT   NM_001034783.2   169		. ,	Rev	TTCTGAGTGAGCCACACAAGG		
Rev   CCTGGTTGTAGAAGGGCAGG	Protein kinase B	AKT1	Fwd	TGAAGACTTTCTGCGGGACC	NM 173986.2	141
AKT serine/threonine kinase 2   AKT2   Fwd   ACGAGGAAGGAGTAAAGCGA   NM_001206146.1   148     Mechanistic target of rapamycin kinase   mTOR1   Fwd   CCTTGGCACAACAGTGCATC   XM_002694043.6   285     Glucose transporter 4   GLUT4   Fwd   GCTTCCAACAGAGTCGGCTCTG   NM_174604.1   174     Reference genes   RPS18   Fwd   TTCCAGCACATCTTGCAGGT   NM_001033614.2   178     Rev   TCACACGTTCCATCGTCATCCCATCC   RM_001034783.2   169     Rev   TTGAATCTTCTGCGCACCCT   NM_001034783.2   169			Rev	CCTGGTTGTAGAAGGGCAGG		
Rev   AGCCAGCCTTCTTTGATGACA     Mechanistic target of rapamycin kinase   mTOR1   Fwd   CCTTGGCACAACAGTGCATC   XM_002694043.6   285     Glucose transporter 4   GLUT4   Fwd   GCTTCCATGTCCTCGTGA   174     Reference genes   RPS18   Fwd   TCCAGCCAGGTCTCATCTGCGCAGT   NM_001033614.2   178     Rev   TCACACGTTCCACGCCACCTC   RM_001034783.2   169     Rev   TTGAATCTTCTGCGCACCTC   NM_001034783.2   169	AKT serine/threonine kinase 2	AKT2	Fwd	ACGAGGAAGGAGTAAAGCGA	NM 001206146.1	148
Mechanistic target of rapamycin kinase   mTOR1   Fwd   CCTTGGCACAACAGTGCATC   XM_002694043.6   285     Glucose transporter 4   GLUT4   Fwd   GCTTCCAACAGAGTCGGCTCTG   NM_174604.1   174     Reference genes   RPS18   Fwd   TTCCAGCACAACAGTCGGCATC   NM_001033614.2   178     Reference genes   RPL 32   Fwd   GCCATCTCTGACTCGGCATC   NM_001034783.2   169			Rev	AGCCAGCCTTCTTTGATGACA		
Rev   AGGTCCTCATGTCCTCGTGA     Glucose transporter 4   GLUT4   Fwd   GCTTCCAACAGATCGGCTCTG   NM_174604.1   174     Reference genes   RPS18   Fwd   TTCCAGCACATCTTGCGAGT   NM_001033614.2   178     Rev   TCACACGTTCCACCTCATCGCACCTC   RM_001033614.2   169     Rev   TTGAATCTTCTGCGCACCTC   NM_001034783.2   169	Mechanistic target of rapamycin kinase	mTOR1	Fwd	CCTTGGCACAACAGTGCATC	XM 002694043.6	285
Glucose transporter 4 GLUT4 Fwd GCTTCCAACAGATCGGCTCTG NM_174604.1 174   Reference genes RPS18 Fwd TTCCAGCACATCTTGCGAGT NM_001033614.2 178   Reference genes RPL 32 Fwd GCCATCTCTGACTCGGCATC NM_001034783.2 169   Rev TTGAATCTTCTGCGCACCTC TTGAATCTTCTGCGCACCTC NM_001034783.2 169			Rev	AGGTCCTCATGTCCTCGTGA		
Reference genes   RPS18   Fwd   TTCCAGCACATCTTGCGAGT   NM_001033614.2   178     Rev   TCACACGTTCCACCTCATCC   TCACACGTTCCACCTCATCC   178     RPL 32   Fwd   GCCATCTCTGACTCGGCATC   NM_001034783.2   169     Rev   TTGAATCTTCTGCGCACCTC   TTGAATCTTCTGCGCACCTC   178	Glucose transporter 4	GLUT4	Fwd	GCTTCCAACAGATCGGCTCTG	NM 174604.1	174
Reference genes   RPS18   Fwd   TTCCAGCACATCTTGCGAGT   NM_001033614.2   178     Rev   TCACACGTTCCACCTCATCC   TCACACGTTCCACCTCATCC   178     RPL 32   Fwd   GCCATCTCTGACTCGGCATC   NM_001034783.2   169     Rev   TTGAATCTTCTGCGCACCTC   TTGAATCTTCTGCGCACCTC   178			Rev	CCAGCCAGGTCTCATTGTAGC		
Rev   TCACACGTTCCACCTCATCC     RPL 32   Fwd     GCCATCTCTGACTCGGCATC   NM_001034783.2     Rev   TTGAATCTTCTGCGCACCCT	Reference genes	RPS18	Fwd	TTCCAGCACATCTTGCGAGT	NM 001033614.2	178
RPL 32 Fwd GCCATCTCTGACTCGGCATC NM_001034783.2 169   Rev TTGAATCTTCTGCGCACCCT			Rev	TCACACGTTCCACCTCATCC		
Rev TTGAATCTTCTGCGCACCCT		RPL 32	Fwd	GCCATCTCTGACTCGGCATC	NM 001034783.2	169
			Rev	TTGAATCTTCTGCGCACCCT		

fetuses (p < 0.05). Regarding the specific adipose depots, the weights of SAT (3.03-fold), TVAT (1.47-fold), and PAT (1.45-fold) were greater in HIGH fetuses than in LOW fetuses, as shown in **Table 3** (35).

#### Adipose Tissue Morphology

The frequency of adipocytes CSA in SAT showed similar patterns between LOW and HIGH fetuses, however, the relative frequency of 201-400  $\mu$ m<sup>2</sup> adipocyte CSA was somewhat higher in LOW fetuses (**Figure 1**, S-1). The frequency of adipocyte CSA in TVAT showed higher frequency of 801-1000  $\mu$ m<sup>2</sup> adipocyte CSA in LOW fetuses and, on the other hand, there were two peaks of

relative frequencies (601-800  $\mu$ m<sup>2</sup> and 1201-1400  $\mu$ m<sup>2</sup>) in HIGH fetuses (**Figure 1**, T-1). The frequency of adipocyte CSA in PAT showed the highest at 801-1000  $\mu$ m<sup>2</sup> in LOW fetuses, and meanwhile at 1001-1200  $\mu$ m<sup>2</sup>in HIGH fetuses (**Figure 1**, P-1). In SAT (p < 0.01) and PAT (p < 0.05), the average adipocyte diameter was greater in HIGH fetuses than in LOW ones (**Figure 1**, S-2, P-2). Consistent with these results, the adipocyte number/unit area of SAT (p < 0.05) and PAT (p < 0.01) was greater in LOW fetuses than in HIGH ones (**Figure 1**, S-3, P-3). There were no differences in adipocyte diameter and adipocyte number/unit area in TVAT between the treatment groups (**Figure 1**, T-1, 2 and 3).

#### TABLE 2 | Primer sequences for miRNA expression measured by real-time PCR.

Representative miRNA	Accession	Mature Sequence	Forward Primer 5'-3'	Length	
bta-miR-15b	MIMAT0003792	20 - uagcagcacaucaugguuuaca - 41	TAGCAGCACATCATGGTTTACA	22	
bta-miR-16b	MIMAT0003525	17 - uagcagcacguaaauauuggc - 37	TAGCAGCACGTAAATATTGGC	21	
bta-miR-19b	MIMAT0004337	54 - ugugcaaauccaugcaaaacuga - 76	TGTGCAAATCCATGCAAAACTGA	23	
bta-miR-27b	MIMAT0003546	61 - uucacaguggcuaaguucugc - 81	TTCACAGTGGCTAAGTTCTGC	21	
bta-miR-33a	MIMAT0009294	6 - gugcauuguaguugcauugca - 26	GTGCATTGTAGTTGCATTGCA	21	
bta-miR-101	MIMAT0003520	49 - uacaguacugugauaacugaa - 69	GCGCTACAGTACTGTGATAACTGAA	25	
bta-miR-130a	MIMAT0009223	55 - cagugcaauguuaaaagggcau - 76	CAGTGCAATGTTAAAAGGGCAT	22	
bta-miR-148a	MIMAT0003522	44 - ucagugcacuacagaacuuugu - 65	TCAGTGCACTACAGAACTTTGT	22	
bta-miR-152	MIMAT0009238	53 - ucagugcaugacagaacuuggg - 74	TCAGTGCATGACAGAACTTGGG	22	
bta-miR-196a	MIMAT0009255	16 - uagguaguuucauguuguuggg - 37	TAGGTAGTTTCATGTTGTTGGG	22	
bta-miR-204	MIMAT0004338	23 - uucccuuugucauccuaugccu - 44	TTCCCTTTGTCATCCTATGCCT	22	
bta-miR-296-3p	MIMAT0009273	47 - gaggguugggcggaggcuuucc - 68	GAGGGTTGGGCGGAGGCTTTCC	22	
bta-miR-378	MIMAT0009305	43 - acuggacuuggagucagaaggc - 64	ACTGGACTTGGAGTCAGAAGGC	22	
U6-F		ctcgcttcggcagcaca	AACGCTTCACGAATTTGCGT	20	

\*bta, Bos taurus; miR, microRNA.

TABLE 3 | Effects of LOW or HIGH maternal nutrition of Wagyu cows during the entirety of gestation on the fetal BW and fat weight.

Item	Weight (g)		<i>p</i> -value	HIGH/LOW <sup>5</sup>	Ratio <sup>3</sup> (%)		<i>p</i> -value
	LOW <sup>1</sup>	HIGH <sup>2</sup>			LOW	HIGH	
Animals, No.	6	6			6	6	
Fetal BW, g	23390.0	32653.0	0.0018	1.396			
fat weight <sup>4</sup> , g	333.0	708.0	0.0004	2.126	5.4	8.1	0.023
TVAT <sup>6</sup>	25.5	37.6	0.018	1.475	0.5	0.5	0.937
SAT	41.5	125.8	0.006	3.032	0.8	1.6	0.032
PAT <sup>7</sup>	82.2	119.2	0.006	1.450	0.4	0.4	0.769
other fat	183.8	425.4					

Data are mean ± standard error. <sup>1,2</sup>Wagyu cows were fed diets providing a low (60%; LOW) or high nutrition level (120%: HIGH), according to the JFSBC (34) nutritional requirements. <sup>3</sup>Ratio of mass relative to the calculated fetal half-carcass (right side) mass. <sup>4</sup>Mass calculated for the right half of the carcass with right-side perirenal adipose tissue. <sup>5</sup>Fold difference between the high-nutrition group and the low-nutrition group for variables with p<0.10. <sup>6</sup>The weights of adipose tissue of the thoracic or peritoneal cavity on the right side of the carcass. <sup>7</sup>The adipose tissue surrounding the right and left kidneys. <sup>\*</sup>These data are from Zhang et al. (35).

## mRNA Expression

In SAT, LOW fetuses had a higher level of LEP (p = 0.045) and tended to have higher PPARG (p = 0.078), CEBPA (p = 0.098), UCP1 (p = 0.072), PGC1 (p = 0.053), IGF2 (p = 0.098), AKT2 (p = 0.087), and GlUT4 (p = 0.092) mRNA levels than HIGH fetuses (**Figures 2A, B**).

In TVAT, LOW fetuses had higher PGC1 $\alpha$  (p = 0.045) and lower ZFP423 (p = 0.042) mRNA levels, and tended to have a higher UCP1 (p = 0.067) mRNA level than HIGH fetuses (**Figure 2A**). Meanwhile, LOW fetuses had lower PPARG(p = 0.059), CEBPA (p = 0.053), FASN (p = 0.086), IGF2 (p = 0.069), and IRS1 (p = 0.071) mRNA levels than HIGH fetuses (**Figure 2A, B**).

In PAT, LOW fetuses had a higher UCP1 (p = 0.046) mRNA level and tended to have a higher PGC1 $\alpha$  (p = 0.073) mRNA level than HIGH fetuses. Conversely, LOW fetuses had lower PPARG (p = 0.066), CEBPA (p = 0.052), LEP (p = 0.068), TNF $\alpha$  (p = 0.079), ZFP423 (p = 0.078), and GLUT4 (p = 0.054) mRNA levels than HIGH fetuses (**Figure 2A, B**).

The expression of PPARG (both LOW and HIGH), CEBPA (both LOW and HIGH), IGF2 (both LOW and HIGH), and AKT2 (HIGH) mRNAs was greater in SAT than in TVAT and PAT (p < 0.05) with no significant difference in the TVAT and PAT (**Figure 3**). The expression of SCD (LOW) and IGF2R (LOW)

mRNAs was greatest in SAT and least in PAT (p < 0.05). The expression of LEP(LOW), TNFa (HIGH), and PI3K (LOW) mRNAs was greater in SAT and TVAT relative to PAT (p < 0.05) without significant difference in the SAT and the TVAT. The expression of UCP1 (LOW) mRNA was greatest in PAT and least in TVAT (p < 0.05). The expression of UCP1 (HIGH), PRDM16 (LOW), PGC1 (both LOW and HIGH), ZFP423 (HIGH), IGF1 (HIGH), IGF2R (HIGH), PI3K (HIGH), mTOR1 (HIGH), and GLUT4 (HIGH) mRNAs was greater in SAT and PAT than in TVAT (p < 0.05), whereas in the SAT and the PAT, they showed no significant difference. Conversely, the expression of IGF1 (LOW) and IGF1R (LOW) m RNAs was greater in TVAT than in SAT and PAT (p < 0.05) without significant difference in the SAT and the PAT. The expression of IGF1R (HIGH) mRNA was greater in PAT than in SAT and TVAT (p < 0.05) without significant difference in the SAT and the TVAT. No significant difference was observed between SAT, TVAT and PAT in the expression of other genes in the nutritional treatment groups not shown so far (Figure 3).

#### Immunohistochemistry

Immunohistochemical analysis of SAT, TVAT, and PAT revealed UCP1-positive staining as a marker of brown adipocytes in both LOW and HIGH fetuses (**Figure 4**).



**FIGURE 1** | (A) Relative frequency distribution of SAT CSA (S-1), diameter (S-2), and number of adipocytes within the same area (S-3) in subcutaneous adipose tissue (SAT) between LOW and HIGH fetuses. (B) Relative frequency distribution of TVAT CSA (T-1), diameter (T-2), and number of adipocytes in the same area (T-3) in thoracic cavity visceral adipose tissue (TVAT) between LOW and HIGH fetuses. (C) Relative frequency distribution of PAT CSA (P-1), diameter (P-2), and number of adipocytes within the same area (P-3) in perirenal adipose tissue (PAT) between LOW and HIGH fetuses. Fetuses:  $260 \pm 8.3$  days of fetal age. LOW: n=6. HIGH: n=6. Values are means with standard errors. Significant differences between fetal groups are denoted by \*p < 0.05 and \*\*p < 0.01.

## miRNA Expression

In SAT, Low fetuses had a higher level of miR-15b (p = 0.021) and tended to have higher levels of miR-33a (p = 0.057) and miR-196a (p = 0.054; **Figure 5**). Conversely, LOW fetuses had a lower level of miR-378 (p = 0.042) and tended to have a lower level of miR-152 (p = 0.088).

In TVAT, LOW fetuses had a higher level of miR-15b (p = 0.011). Meanwhile, LOW fetuses had lower levels of miR-33a (p = 0.014), miR-204 (p = 0.022), and miR-378 (p = 0.009) and tended to have a lower level of miR-101 (p = 0.059; **Figure 5A**).

In PAT, LOW fetuses had higher levels of miR-196a (p = 0.018) and miR-378 (p = 0.047) than HIGH fetuses. Similarly, LOW fetuses tended to have a higher level of miR-101 (p = 0.072). Conversely, LOW fetuses had lower levels of miR-16b (p = 0.013) and miR-27b (p = 0.034) than HIGH fetuses. Simultaneously, LOW fetuses tended to have lower levels of miR-33a (p = 0.064), miR-204 (p = 0.053), and miR-296-3p (p = 0.069; **Figure 5A**).

The expression of miR-33a (LOW) and 130a (LOW) was greater in SAT than in TVAT and PAT (p < 0.05) with no significant difference in the TVAT and the PAT (**Figure 5B**). The expression of miR-15b (LOW) and 196a (LOW) was greatest in SAT and least in TVAT (p < 0.05). The expression of miR-15b (HIGH), 16b (LOW), 101 (LOW), and 296-3p (HIGH) was greater in SAT and PAT relative to TVAT (p < 0.05) without significant difference in the SAT and the PAT. The expression of miR-16b (HIGH), 152 (HIGH), and 378 (LOW) was greater in PAT than in SAT and TVAT (p < 0.05) with no significant difference in the SAT and the TVAT. The expression of miR-196a (HIGH) was greatest in TVAT and least in SAT (p < 0.05). No significant difference was observed between SAT, TVAT and PAT in the expression of other miRNAs in the nutritional treatment groups not shown so far (**Figure 5B**).

## DISCUSSION

The function of adipose tissue changes with development. In the newborn, BAT is needed to ensure an effective response to the



based on the mean of the target gene Ct value of LOW and HIGH fetuses. Fetuses:  $260 \pm 8.3$  days of fetal age. LOW: n=6. HIGH: n=6. \*Significant difference and <sup>†</sup>trend ( $\rho < 0.05$  and  $\rho < 0.1$ , respectively) between LOW and HIGH fetuses.

extrauterine environment. Overall adipose tissue mass increases during late gestation, with a mixture of white and brown adipocytes. After that, during postnatal life, some, but not all, adipose depots are replaced by white adipocytes. The changes in maternal nutrition at the mid and the late gestation modify adipose tissue development profiles (12, 42). The gene expression change occurs in an adipose tissue depot-specific manner in offspring born to mothers fed lower nutrition from early to midgestation in cattle (43). Maternal low nutrition decreased the expression of Adipocyte Protein (AP) 2 and GLUT4 mRNAs and increased the expression of Cluster of Differentiation (CD) 36 mRNAs in PAT, but not in SAT of offspring in crossbred Angus cattle (43). However, the detailed differential-responses and its relationships of mass and molecular dynamics between SAT, TVAT and PAT in fetuses of different maternal nutrition have not been examined well in cattle. In this study, we demonstrated that lower or higher maternal nutrition during gestation could alter adipose tissue mass, adipocyte size, and gene expression in an adipose-tissue-specific manner in fetuses of Wagyu cattle. In all adipose tissue of LOW fetuses, gene expression analysis

indicated enhanced BAT development. In addition, gene expression related to WAT differed between SAT and the other adipose tissues (TVAT and PAT), suggesting the different susceptibility of adipose tissue to maternal nutrition.

There is a need to develop an efficient feeding system because the cost of feeding cattle is increasing. Although the body adipose tissue of beef cattle is not only for energy storage but also an endocrine organ affecting metabolism (44) as well as meat quality and quantity (3), in the beef industry carcass adipose tissue is practically and economically wasted, apart from intramuscular adipose tissue (45). Regulating the development of adipose tissue in cattle could lead to the development of an efficient feeding system. In cows, not only growth but also reproduction and maintenance of body functions require adequate nutrition. Animals use energy and nutrients obtained from feed in various ways. Ferrell and Jenkins (46) reported that, in mature beef cows, maintenance requirements represent approximately 70% to 75% of the total annual energy requirements. In this study, we established two nutritional groups allocated 60% and 120% of nutritional requirements during gestation and identified



clear phenotypic differences in fetuses between them (35). Chronic restriction of maternal nutrition has been indicated to reduce basal metabolic rate (47, 48) and to impact fetal development (42, 49). In this study, differences in the development of adipocytes of SAT, TVAT, and PAT between LOW and HIGH fetuses were shown, that namely, adipose tissue mass increased in HIGH fetuses. The expression of UCP1 and PGC1 $\alpha$  mRNA increased or tended to increase in SAT, TVAT, and PAT of LOW fetuses and only in SAT of LOW fetuses had more LEP mRNA and tended to have more PPARG, CEBPA, and GLUT4 mRNA. Thus Maternal nutrition would thus strongly affect the accumulation of adipocytes and the activation of their gene expression in the fetus.

As an endocrine organ, adipose tissue is not only involved in energy storage but also acts as a complex, important, and metabolically active part of the body (44). Adipose tissue is scattered throughout the whole body, but makes up 5% to 35% of cattle body mass, which is dependent on age, genotype, and nutrition (4). In adipose tissue, there are three major depot locations, visceral, subcutaneous, and intermuscular depots, which can be further subdivided into smaller depots defined by anatomical location (perirenal and omental) (4). In Wagyu cattle, with growth and fattening, subcutaneous and visceral adipose tissue exhibits particular development that differs from the findings in European breeds such as Holstein, German Angus, and Belgian Blue cattle (3). In mammals including cattle, adipose tissue has been classified into two distinct types: one is white adipose tissue, which has a major function in energy storage; and the other is brown adipose tissue, which is specialized for energy expenditure (4). In recent time, beige adipose tissue, which is a mixture of brown and white adipocyte, was identified. Beige adipocyte is transdifferentiated from WAT and has many similar morphological and functional properties with brown adipocyte (50).

In cattle, the perirenal adipose tissue starts to appear in fetuses from around day 80 of gestation, followed by visceral, subcutaneous, and intermuscular adipose tissue from day 180 of gestation onward, whereas intramuscular adipocytes in fetus muscles starts to develop from mid- and late-gestation (6, 8), and discernible intramuscular adipocytes filled with lipid develop after birth in earnest (4). Considering the results obtained in this study, given the specific functions and different distributions of individual adipose tissue depots, nutritional interventions during gestation could impact on fetal adipose tissue development in



diverse ways. However, few studies focusing on ruminants have evaluated the effects of suboptimal maternal nutrition on the development of fetal adipose tissue. Jennings et al. (51) found that maternal high (146% nutrition requirement) and low (72% g nutrition requirement) nutrition during mid-gestation did not affect the expression of genes related to adipogenesis in subcutaneous adipose tissue of Angus crossbred fetuses at d 180. These results suggest that fetal growth characteristics are not affected by the level of maternal nutritional manipulation imposed in the study during mid-gestation. While, Long et al. (43) fattened the offspring exposed to 55% maternal nutrition of during early gestation, indicated no differences in distribution of

subcutaneous and perirenal adipose tissue compared with the control offspring, but the expression of AP2, CD36, and GLUT4 in the perirenal adipose tissue was suppressed in low nutrition group. Regardless of the animal species, the effects of maternal nutrition on fetal development are supposed to be affected by the timing of treatment during gestation (49, 52), although here we manipulated maternal nutrition during the entirety of gestation.

In this study, the adipocyte diameters of SAT and PAT were greater in HIGH fetuses, while there were no differences in adipocyte diameter in TVAT between LOW and HIGH fetuses. This suggested that specific adipose tissue depots showed different responses to suboptimal maternal nutrition during



**FIGURE 5** Comparison of miniNAs in adipose tissues. (A) Comparison of fold change (LOW/HIGH) of miniNA abundance in subcutaneous (SAT), thoracic cavity visceral (TVAT), and perirenal adipose tissues (PAT) between LOW and HIGH fetuses in Wagyu cattle. The horizontal dotted line (at the value "1") showed the relative miRNA expression of the HIGH fetuses. The foldchange was calculated as the relative expression based on the mean of the target gene Ct value of LOW and HIGH fetuses. (B) Comparison of mRNA abundance between SAT, TVAT, and PAT in the LOW and the HIGH fetuses in Wagyu cattle. Fetus age: Fetuses: 260 ± 8.3 days of fetal age. LOW: n=6. HIGH: n=6. "Significant difference and <sup>†</sup>trend ( $\rho < 0.05$  and  $\rho < 0.1$ , respectively) between LOW and HIGH fetuses. ( $\rho < 0.05$ ) between SAT, TVAT, and PAT in the LOW and the HIGH fetuses.

pregnancy. Moreover, it was also suggested that the adipocytes of SAT and PAT were more sensitive to nutritional deficiencies. In calves born from dams fed a restricted level of protein, the mass weight of perirenal adipose tissue, adipocyte size, and lipogenic activities were reported to be similar to those in control calves at birth (53).

We estimated the number of adipocytes (**Figure 6**) based on the adipocyte diameter and mass of adipose tissue in SAT, TVAT, and PAT (35). In this simulation, we used 0.92 g/cm<sup>3</sup> as the adipose tissue density (54) and assumed that the adipocytes were spherical for this calculation. The results showed that the numbers of adipocytes in SAT (2.3-fold), TVAT (1.6-fold) were greater in HIGH fetuses than in LOW ones (p < 0.01; **Figure 6**). This suggests that maternal nutrition would alter the number of adipocytes in adipose tissue, with SAT and TVAT being particularly sensitive to this. However, the number of adipocytes could be increased after birth by proliferation (55).

In the immunohistochemical observation on UCP1-positive status, SAT, TVAT, and PAT seemed to show greater numbers of

brown adipocytes in LOW fetuses than in HIGH fetuses. These findings are supported by the higher UCP1 mRNA expression in SAT, TVAT, and PAT (Figure 4). This suggested that maternal overnutrition could suppress brown adipocyte development during gestation. Similar to this result, when the dams consumed a suboptimal amount of nutrients during the final month of gestation, birth weight and adipose tissue mass were reduced, but this is highly likely to reflect a reduction in adipose tissue stores rather than a reduction in the amount of brown adipose tissue in mammals (12). Intriguingly, the reduced amount of adipose tissue present in newborns has a greater capacity to maintain UCP1 as a BAT biomarker, which could be indicative of a protective mechanism against subsequent exposure to some environment with temperature change or an obesogenic environment in human (12). Furthermore, enhanced maternal nutrition from mid- to late gestation could accelerate the activity of glucocorticoids and a series of inflammatory responses in newborns when key inflammatory genes were upregulated (56). However, maternal overfeeding (150% of control) during mid- to late gestation did not affect the weight of



perirenal BAT or the adipocyte diameter of fetuses, but increased some adipogenic factor, PPARG, and in lipoprotein lipase, adiponectin, and LEP mRNA expression in PAT (57).

In the adipogenesis, PPARG, CEBPA, SCD, FASN, FABP 4, ZFP423, and LEP have the crucial role (13-17). The changes in the expression of various mRNAs in this study suggested that the adipogenesis of Wagyu fetuses could be susceptible to change due to maternal nutritional status during gestation in a manner dependent on each particular adipose tissue depot. The formation and composition of adipose tissue in cattle are derived from a complex process. They are controlled by multiple parameters including genetic factors, nutritional status, feeding system, species, and sex in cattle (58). In this study, the pattern of gene expression in SAT differed from those in TVAT and PAT. Regarding SAT, HIGH fetuses had 3-fold greater mass than LOW fetuses, while for TVAT and PAT, HIGH fetuses had only 1.4-fold greater mass (35). In addition, SAT from LOW fetuses had greater expression of PPARG, CEBPA, and LEP mRNA, which might suggest that they were trying to develop WAT because the formation of WAT was delayed due to maternal lower nutrition compared with that from HIGH fetuses. Moreover, only in SAT, LOW fetuses tended to have higher levels of IGF2, AK2, and GLUT4 mRNA. Thus, in SAT, depending on the maternal nutritional level, LOW fetuses showed different patterns of mRNA expression related to genes involved in growth and glucose metabolism compared with the findings for TVAT and PAT. Enhanced LEP mRNA expression indicates elevated insulin sensitivity (59), while enhanced GLUT4 expression indicates elevated glucose intake (60). In addition, increased expression of PPARG and CEBPA mRNA in SAT indicates that adipocyte differentiation is activated (61, 62).

Conversely, in TVAT and PAT, LOW fetuses tended to have lower expression of PPARG and CEBPA mRNA and, in PAT, also tended to have lower expression of LEP mRNA, showing the opposite tendency to SAT. SAT is a layer of subcutaneous fat is located between the dermis and the underlying fascia on the outer muscle. SAT is not only serving as a reserve source of energy for the body, but also SAT helps to physically insulate the body from cold (63) and radiates heat in the case of containing BAT in a part of SAT. Moreover, in all of SAT, TVAT, and PAT, LOW fetuses had higher levels of UCP1 and PGC1 amRNA, indicating that brown adipocyte formation was activated in LOW fetuses. Heat-producing adipocytes, brown adipocytes, drive heat production through the close coordination of substrate supply with the mitochondrial oxidative machinery and effectors that control the rate of substrate oxidation (64, 65). Brown adipocyte as a heat production effector specifically expresses UCP1, which is the best characterized marker of BAT (66). With regard to adipose tissue mass, LOW fetuses had only half the carcass mass of HIGH fetuses (35), resulting in the heat-producing ability also being lower. Landis et al. (67) reported the expression of UCP mRNA in the tail-head subcutaneous adipose tissue of cross-bred fetuses though the gene expression level was low. These dynamics of gene expression suggested that, in LOW fetuses, brown adipocytes are activated more for thermogenesis to increase the potential for survival.

In this study, in PAT, LOW fetuses tended to have a lower level of GLUT4 mRNA. Undernutrition during late pregnancy in sheep was reported to reduce the expression of GLUT4 protein in renal adipose tissue and simultaneously generate glucose resistance in offspring at 1 year of age (68). However, the renal and omental adipose tissue mass levels of nutrient restricted group during late gestation were increased compared with those of control group (68). Further research is needed to investigate whether LOW fetuses exhibit an increase in mass later in life. In PAT, lower maternal nutrition increased the levels of PPARG and UCP1 mRNAs in fetuses compared with higher maternal nutrition and a positive correlation between the levels of PPARG and UCP1 mRNAs was reported in sheep (69). These findings were not consistent with our results showing decreased abundance of PPARG mRNA and increased abundance of UCP1 mRNA in LOW fetuses.

Wagyu (Japanese Black) cattle is a unique breed with a high capacity to produce marbled meat. In Wagyu, not only did intramuscular adipose tissue increase 12-fold (2.18% to 26.77%) but also SAT increased 14-fold (3.11% to 44.26%)



**FIGURE 7** | Hypothetical scheme of the influences of maternal under- or overnutrition on the associations between fetal SAT, TVAT, and PAT development in weight, histochemical properties, gene expression (related to adipogenesis, growth factors, and glucose metabolism), and miR expression. Inequality sign is based on p < 0.10.

during fattening (8 to 26 months of age), which contrasts with the finding for PAT (5.25-fold: 4.58% to 24.07%; 3). Conceivably, this ability could be revealed during the fetal development period, and this potential is likely to be influenced by maternal nutrition during gestation. In this study, the sensitivity of fetal SAT to maternal nutrition was quite high.

Notably, studies in mice have shown that ZFP423 is a transcription factor responsible for the adipogenic commitment of progenitor cells (70). The expression of ZFP423 commits progenitor cells to the adipogenic lineage and ensures their differentiation into pre-adipocytes, subsequently inducing PPARG expression, which results in their terminal differentiation (15). The importance of ZFP423 in bovine adipogenesis was further confirmed (16). Shao et al. (71) reported that Fetal development of subcutaneous white adipose tissue is dependent on ZFP423. In this study, in TVAT and PAT, LOW fetuses had a lower expression level of ZFP423 mRNA than HIGH fetuses (p<0.10). On the other hand, it was suggested that LOW fetuses activated white adipose tissue formation in SAT because of increased ZFP423 expression.

The brown adipocytes originate primarily from cells in the dermomyotome expressing engrailed 1 (En1), myogenic factor 5

(Myf5), and paired-box protein 7 (Pax7), which can also give rise to muscle cells during the fetal period (72, 73). Thus, the fate of myogenesis during fetal development might be associated with brown adipocytes, which could in turn be affected by maternal nutrition. Although in mouse, Yang et al. (74) previously observed that maternal overnutrition increased the white adipogenesis of progenitors in highly nourished fetuses, while high maternal nutrition during lactation also impaired the thermogenic function of BAT in offspring (75). Therefore, accompanied by lower levels of UCP1, PRDM16, and PGC1 $\alpha$ mRNAs in HIGH fetuses, it is suggested that the manipulation of maternal nutrition, especially long-term maternal overnutrition, might adversely affect brown adipose tissue mass and its function in adipose depots of the fetus.

MicroRNAs have been shown to be important for various biological processes including adipose tissue development. This time we have chosen miRNAs which powerfully affect gene expression related adipogenesis. It has been demonstrated that microRNAs play a critical role in regulating differentiation and function in both WAT and BAT (76, 77). In this study, similar to the results of mRNA expression, differential expression of

miRNAs was observed among adipocytes of SAT, TVAT, and PAT (**Figure 5A**). These findings suggested that the manipulation of maternal nutrition throughout gestation could change the miRNA expression dynamics and differentially regulate the development of each adipocyte depot.

miR-15b expression increased in SAT and TVAT of LOW fetuses, but not in PAT. miR-15b has been found to regulate lipid metabolism negatively in adipocytes (regulating DLK1 as a target gene; 25). Increased miR-15b expression in SAT and TVAT of LOW fetuses might reduce lipid metabolism and lead to decreases in lipid content in adipocytes and adipocyte differentiation by reducing the amount of DLK1 (25).

A number of key transcription factors including PPARG and CEBPA/B are known to regulate adipocyte terminal differentiation and lipid metabolism (78), while miRNAs have been demonstrated to regulate adipocyte differentiation through both direct and indirect targeting of these critical transcription factors, as well as their downstream targets (77). PPARG is considered the master regulator of adipocyte differentiation and is a direct target of miR-27a/b (79) and miR-130 (80). Although PPARG mRNA exhibited different expression in adipose tissue among SAT, TVAT, and PAT, miR-27b decreased the expression only in PAT and miRNA-130a did not show any differences in expression in each adipose tissue depot. This suggested that maternal nutrition could affect adipose tissue development, but not through these miRNAs in fetuses. Meanwhile, the inhibition of miR-27b in glucocorticoid-treated mice was found to increase energy expenditure, reduce body weight, and improve the regulation of glucose homeostasis (31). These effects are likely mediated through the targeting of PRDM16, although numerous other factors are involved in promoting BAT function, including PPARA and PPARG coactivator 1-beta (PGC-1 $\beta$ ), which have also been identified as targets of miR-27 (81).

Interestingly, miR-196a plays an essential role in BAT progenitor cells and induces the "browning" of WAT, with enhanced expression of BAT genes, inducing PRDM16, UCP1, and PGC-1 $\alpha$  (18: rodent). Moreover, miR-196a promotes "browning" by directly binding and suppressing Homeobox C8 (HoxC8), a determinant of white adipogenesis (82: vertebrate; 28: mouse). Because the development of BAT in TVAT of LOW fetuses is promoted with no change of miR-196a expression between LOW and HIGH fetuses, it was suggested that miR-196a was not responsible for promoting BAT development.

miR-378 has been characterized as another positive regulator of BAT (26). In transgenic mice, miR-378 is associated with increased BAT mass and decreased WAT mass, which might be caused by BAT expansion and increased energy expenditure (26). miR-378 was shown to be increased in PAT of LOW fetuses, while UCP1 and PGC-1 $\alpha$  mRNA expression was also increased in PAT. It appears that malnutrition could promote BAT development in PAT of LOW fetuses. However, the expression of miR-378 in SAT and TVAT indicated the opposite trend to that in PAT, so it seems that the biological function of miR-378 in PAT differs from those in SAT and TVAT, which is altered by maternal nutrition.

miR-204 showed a lower level in TVAT and PAT of LOW fetuses, but not in SAT. Indeed, miR- has been found to target

runt-related transcription factor 2 (RUNX2), which is considered the master regulator of osteoblast differentiation and is one of the main sites of miRNA-mediated adipocyte/osteoblast cell fate determination, resulting in impaired osteogenesis and improved adipogenesis (24). It is suggested that malnutrition during gestation might influence adipose development through downregulating miR-204.

miR-16b regulates metabolism, cell cycle, and inflammatory stress response (83, 84). miR-33a suppresses UCP1 mRNA expression by regulating target genes in BAT (32). In SAT, LOW fetuses retained higher UCP1 mRNA expression although miR-33a expression was higher than that in HIGH fetuses. Meanwhile, there was reasonable interaction between TVAT and PAT, indicating decreased miR-33a and enhanced UCP1 mRNA expression. miR-101 inhibits cell differentiation and induces apoptosis (33). There were different expression patterns of miR-101 expression between TVAT and PAT. miR-152 was previously reported to downregulate preadipocyte proliferation and upregulate differentiation in an in vitro experiment using 3T3-L1 (29). Only in SAT, LOW fetuses had a lower abundance of miR-152. This suggests that adipocyte differentiation might be activated more in SAT. miR296-3p enhances angiogenesis and cellular proliferation and conversely downregulates apoptosis (27). Only in PAT, decreased expression of miR-296-3p was observed in LOW fetuses, suggesting that angiogenesis and cellular proliferation might be activated in PAT. However, more recently, updated information regarding these miRNAs has been reported (85). We have to carefully examine the related information and verify the relationship between the obtained data and adipose tissue development in bovine fetuses.

Finally, when comparing the differences in gene expression between adipose tissue depots, 10 genes showed a similar relationship between LOW and HIGH fetuses (Figure 3). However, other genes showed different patterns of gene expression between LOW and HIGH fetuses. In particular, the expression of PPARG, CEBPA, and IGF2 mRNA was higher in SAT than in TVAT and PAT in both LOW and HIGH fetuses, and it was speculated that WAT formation and development were enhanced in SAT. On the other hand, UCP1 as a marker of Brown adipose tissue has higher expression in PAT than TVAT, suggesting that PAT has more Brown adipocytes. In general, it was suggested that the molecule dynamics in SAT and PAT were more activated compared with the TVAT. When comparing the differences in miRNA expression between the adipose tissue depots, no differences of half miRNAs expression were observed between SAT, TVAT, and PAT, and the related pattern was different between the LOW and HIGH fetuses (Figure 5B). There seems to be many cases of higher miRNA expression in the SAT and PAT than in TVAT. However, further studies are needed regarding these reasons.

## CONCLUSION

The present study revealed that maternal nutrition during gestation affected the development of adipose tissue by changing not only mass but also mRNA and miRNA

expression in an adipose depot-specific manner in fetuses of fatty breed, Wagyu cattle (**Figure 7**). These findings suggest that low maternal nutrition would lead to the development of BAT in fetal adipose tissues and this BAT activation in LOW fetuses might be a priority and delayed WAT formation due to lower nutrition. Intriguingly, more significant differences in mRNA expression were observed in SAT and PAT than in TVAT. Moreover, in SAT and PAT, HIGH fetuses had a greater diameter of adipocytes than LOW fetuses. Meanwhile, the findings also suggested that lower maternal nutrition during gestation could suppress the WAT development in TVAT and PAT, but would accelerate that in SAT. The sensitivity of fetuses to low maternal nutrition in SAT would differ from that in TVAT and PAT. Various miRNAs showed significant differences between the LOW and HIGH fetuses in an adipose tissue-specific manner.

## DATA AVAILABILITY STATEMENT

The data sets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/**Supplementary Material**.

## ETHICS STATEMENT

The animal study was reviewed and approved by Kagoshima University Animal Care and Use Committee (A18007).

# **AUTHOR CONTRIBUTIONS**

YZ: Conceptualization, methodology, software, writing-original draft preparation. KoO: Surgery management, animal care, data

## REFERENCES

- Hornstein I, Wasserman A. Sensory Characteristics of Meat. Part 2-Chemistry of Meat Flavor. In: JF Price, BS Schweigert, editors. *The Science* of Meat and Meta Products, 3rd ed. Westport, CT: Food and Nutrition Press (1987). p. 329–47.
- Wheeler TL, Cundiff LV, Koch M. Effect of Marbling Degree on Beef Palatability in Bos Taurus and Bos Indicus Cattle. J Anim Sci (1994) 72:3145–51. doi: 10.2527/1994.72123145x
- Gotoh T, Albrecht E, Teuscher F, Kawabata K, Sakashita K, Iwamoto H, et al. Differences in Muscle and Fat Accretion in Japanese Black and European Cattle. *Meat Sci* (2009) 82:300–8. doi: 10.1016/j.meatsci.2009.01.026
- Bonnet M, Cassar-Malek I, Chilliard Y, Picard B. Ontogenesis of Muscle and Adipose Tissues and Their Interactions in Ruminants and Other Species. *Animal* (2010) 4:1093–109. doi: 10.1017/S1751731110000601
- Fève B. Adipogenesis: Cellular and Molecular Aspects. Best Pract Res Clin Endocrinol Metab (2005) 19:483–99. doi: 10.1016/j.beem.2005.07.007
- Du M, Tong J, Zhao J, Underwood KR, Zhu M, Ford SP, et al. Fetal Programming of Skeletal Muscle Development in Ruminant Animals. J Anim Sci (2010) 88(13 Suppl):E51–60. doi: 10.2527/jas.2009-2311
- Prior RL, Laster DB. Development of the Bovine Fetus. J Anim Sci (1979) 48:1546–53. doi: 10.2527/jas1979.4861546x
- 8. Albrecht E, Kuzinski J, Komolka K, Gotoh T, Maak S. Localization and Abundance of Early Markers of Fat Cell Differentiation in the Skeletal Muscle

curation/investigation/validation. KaO: Reproduction management, animal care, data curation investigation validation. YG: Reproduction management, animal care, data curation/investigation/validation. IO: Reproduction management, data curation/investigation/validation. SM: Data curation/investigation/validation. MS: Data curation/ investigation/validation. SR: Physiological data curation, methodology writing—review and editing. TG: Supervision, conceptualization, funding acquisition, writing—review and editing. All authors contributed to the article and approved the submitted version.

## **FUNDING**

This study received funding from Leave a Nest Co., Ltd., the Canon Foundation (R15-0089), Japan Racing Association and Kakenhi (No. 26310312 and19KT0013) from the Japan Society for the Promotion of Science. The authors declare that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## ACKNOWLEDGMENTS

The authors wish to thank Aoi Kinoshita, Rena Saneshima, Yukiko Nagao, Yasuko Okamura, and Makoto Futohashi for their technical assistance with the sampling. The authors also thank Edanz (https://jp.edanz.com/ac) for editing the English text of a draft of this manuscript.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021. 797680/full#supplementary-material

of Cattle During Growth Are DLK1-positive Cells the Origin of Marbling Flecks? *Meat Science* (2015) 100:237–45. doi: 10.1016/j.meatsci.2014.10.012

- Ford SP, Hess BW, Schwope MM, Nijland MJ, Gilbert JS, Vonnahme KA, et al. Maternal Undernutrition During Early to Mid-Gestation in the Ewe Results in Altered Growth, Adiposity, and Glucose Tolerance in Male Offspring. J Anim Sci (2007) 85:1285–94. doi: 10.2527/jas.2005-624
- Funston RN, Larson DM, Vonnahme KA. Effects of Maternal Nutrition on Conceptus Growth and Offspring Performance: Implications for Beef Cattle Production. J Anim Sci (2010) 88:E205–15. doi: 10.2527/ jas.2009-2351
- Rodríguez A, Ezquerro S, Méndez-Giménez L, Becerril S, Frühbeck G. Revisiting the Adipocyte: A Model for Integration of Cytokine Signaling in the Regulation of Energy Metabolism. *Am J Physiol Endocrinol Metab* (2015) 309:E691–714. doi: 10.1152/ajpendo.00297.2015
- Symonds ME, Pope M, Sharkey D, Budge H. Adipose Tissue and Fetal Programming. *Diabetologia* (2012) 55:1597–606. doi: 10.1007/s00125-012-2505-5
- Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose Expression of Tumor Necrosis Factor-Alpha: Direct Role in Obesity-Linked Insulin Resistance. *Science* (1993) 259:87–91. doi: 10.1126/science.7678183
- Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, et al. Selective Disruption of Pparγ2 Impairs the Development of Adipose Tissue and Insulin Sensitivity. *Proc Natl Acad Sci* (2004) 101:10703–8. doi: 10.1073/pnas. 0403652101

- Gupta RK, Mepani RJ, Kleiner S, Lo JC, Khandekar MJ, Cohen P, et al. Zfp423 Expression Identifies Committed Preadipocytes and Localizes to Adipose Endothelial and Perivascular Cells. *Cell Metab* (2012) 15:230–9. doi: 10.1016/ j.cmet.2012.01.010
- Huang Y, Zhao JX, Yan X, Zhu MJ, Long NM, McCormick RJ, et al. Maternal Obesity Enhances Collagen Accumulation and Cross-Linking in Skeletal Muscle of Ovine Offspring. *PloS One* (2012) 7:e31691. doi: 10.1371/ journal.pone.0031691
- De Jager N, Hudson NJ, Reverter A, Barnard R, Café LM, Greenwood PL, et al. Gene Expression Phenotypes for Lipid Metabolism and Intramuscular Fat in Skeletal Muscle of Cattle. J Anim Sci (2013) 91:1112–28. doi: 10.2527/jas.2012-5409
- Mori M, Nakagami H, Rodriguez-Araujo G, Nimura K, Kaneda Y. Essential Role for miR-196a in Brown Adipogenesis of White Fat Progenitor Cells. *PloS Biol* (2012) 10:e1001314. doi: 10.1371/journal.pbio.1001314
- Menghini R, Marchetti V, Cardellini M, Hribal ML, Mauriello A, Lauro D, et al. Phosphorylation of GATA2 by Akt Increases Adipose Tissue Differentiation and Reduces Adipose Tissue-Related Inflammation: A Novel Pathway Linking Obesity to Atherosclerosis. *Circulation* (2005) 111:1946–53. doi: 10.1161/01.CIR.0000161814.02942.B2
- Khan AH, Pessin JE. Insulin Regulation of Glucose Uptake: A Complex Interplay of Intracellular Signaling Pathways. *Diabetologia* (2002) 45:1475–83. doi: 10.1007/s00125-002-0974-7
- Fernyhough ME, Okine E, Hausman G, Vierck JL, Dodson MV. PPARgamma and GLUT-4 Expression as Developmental Regulators/Markers for Preadipocyte Differentiation Into an Adipocyte. *Domest Anim Endocrinol* (2007) 33:367–78. doi: 10.1016/j.domaniend.2007.05.001
- Lee P, Jung SM, Guertin DA. The Complex Roles of mTOR in Adipocytes and Beyond. Trends Endocrinol Metab (2017) 28:319–39. doi: 10.1016/j.tem.2017.01.004
- McGregor RA, Choi MS. microRNAs in the Regulation of Adipogenesis and Obesity. Curr Mol Med (2011) 11:304–16. doi: 10.2174/156652411795677990
- Huang J, Zhao L, Xing L, Chen D. MicroRNA-204 Regulates Runx2 Protein Expression and Mesenchymal Progenitor Cell Differentiation. *Stem Cells* (2010) 28:357–64. doi: 10.1002/stem.288
- Andersen DC, Jensen CH, Schneider M, Nossent AY, Eskildsen T, Hansen JL, et al. MicroRNA-15a Fine-Tunes the Level of Delta-Like 1 Homolog (DLK1) in Proliferating 3T3-L1 Preadipocytes. *Exp Cell Res* (2010) 316:1681–91. doi: 10.1016/j.yexcr.2010.04.002
- Pan D, Mao C, Quattrochi B, Friedline RH, Zhu L, Jung DY, et al. MicroRNA-378 Controls Classical Brown Fat Expansion to Counteract Obesity. *Nat Commun* (2014) 5:4725. doi: 10.1038/ncomms5725
- Li H, Ouyang XP, Jiang T, Zheng XL, He PP, Zhao GJ. MicroRNA-296: A Promising Target in the Pathogenesis of Atherosclerosis? *Mol Med* (2018) 24:12. doi: 10.1186/s10020-018-0012-y
- Schulz TJ, Huang TL, Tran TT, Zhang H, Townsend KL, Shadrach JL, et al. Identification of Inducible Brown Adipocyte Progenitors Residing in Skeletal Muscle and White Fat. *Proc Natl Acad Sci USA* (2011) 108:143–8. doi: 10.1073/pnas.1010929108
- Fan Y, Gan M, Tan Y, Chen L, Shen L, Niu L, et al. Mir-152 Regulates 3t3-L1 Preadipocyte Proliferation and Differentiation. *Molecules* (2019) 24:3379. doi: 10.3390/molecules24183379
- 30. Shi C, Zhang M, Tong M, Yang L, Pang L, Chen L, et al. miR-148a is Associated With Obesity and Modulates Adipocyte Differentiation of Mesenchymal Stem Cells Through Wnt Signaling. *Sci Rep* (2015) 22:9930. doi: 10.1038/srep09930
- 31. Kong X, Yu J, Bi J, Qi H, Di W, Wu L, et al. Glucocorticoids Transcriptionally Regulate miR-27b Expression Promoting Body Fat Accumulation via Suppressing the Browning of White Adipose Tissue. Diabetes (2015) 64:393-404. doi: 10.2337/db14-0395
- 32. Afonso MS, Verma N, Solingen CV, Cyr Y, Sharma M, Perie L, et al. MicroRNA-33 Inhibits Adaptive Thermogenesis and Adipose Tissue Beiging. Arteriosclerosis Thrombosis Vasc Biol (2021) 41:1360–73. doi: 10.1161/ATVBAHA.120.315798
- Guan H, Dai Z, Ma Y, Wang Z, Liu X, Wang X. MicroRNA-101 Inhibits Cell Proliferation and Induces Apoptosis by Targeting EYA1 in Breast Cancer. Int J Mol Med (2016) 37:1643–51. doi: 10.3892/ijmm.2016.2557
- 34. National Agriculture and Food Research Organization (NARO). *Japanese Feeding Standard for Beef Cattle (JFSBC)*. Tokyo: Japan Livestock Industry Association, corporation (2008).

- 35. Zhang Y, Otomaru K, Oshima K, Goto Y, Oshima I, Muroya S, et al. Effects of Low and High Levels of Maternal Nutrition Consumed for the Entirety of Gestation on the Development of Muscle, Adipose Tissue, Bone, and the Organs of Wagyu Cattle Fetuses. *Anim Sci J* (2021) 92:e13600. doi: 10.1111/ asj.13600
- 36. Zhu MJ, Han B, Tong J, Ma C, Kimzey JM, Underwood KR, et al. AMP-Activated Protein Kinase Signaling Pathways are Down Regulated and Skeletal Muscle Development Impaired in Fetuses of Obese, Over-Nourished Sheep. J Physiol (2008) 586:2651–64. doi: 10.1113/jphysiol.2007.149633
- Tong JF, Yan X, Zhu MJ, Ford SP, Nathanielsz PW, Du M. Maternal Obesity Downregulates Myogenesis and Beta-Catenin Signaling in Fetal Skeletal Muscle. Am J Physiol Endocrinol Metab (2009) 296:E917–24. doi: 10.1152/ ajpendo.90924.2008
- Paradis F, Wood KM, Swanson KC, Miller SP, McBride BW, Fitzsimmons C. Maternal Nutrient Restriction in Mid-to-Late Gestation Influences Fetal mRNA Expression in Muscle Tissues in Beef Cattle. *BMC Genomics* (2017) 18:632. doi: 10.1186/s12864-017-4051-5
- Martin DM, Jones AK, Pillai SM, Hoffman ML, McFadden KK, Zinn SA, et al. Maternal Restricted- and Over-Feeding During Gestation Result in Distinct Lipid and Amino Metabolite Profiles I the Longissimus Muscle of the Offspring. *Front Physiol* (2019) 10:515. doi: 10.3389/fphys.2019.00515
- Gauvin MC, Pillai MS, Reed SA, Stevens JR, Hoffman ML, Jones AK, et al. Poor Maternal Nutrition During Gestation in Sheep Alters Prenatal Muscle Growth and Development in Offspring. J Anim Sci (2020) 98:skz388. doi: 10.1093/jas/skz388
- Asano H, Yamada T, Hashimoto O, Umemoto T, Sato R, Ohwatari S, et al. Diet-Induced Changes in Ucp1 Expression in Bovine Adipose Tissues. *Gen Comp Endocrinol* (2013) 184:87–92. doi: 10.1016/j.ygcen.2013.01.006
- 42. Du M, Wang B, Fu X, Yang Q, Zhu MJ. Fetal Programming in Meat Production. *Meat Sci* (2015) 109:40–7. doi: 10.1016/j.meatsci.2015.04.010
- 43. Long NM, Prado-Cooper MJ, Krehbiel CR, DeSilva U, Wettemann RP. Effects of Nutrient Restriction of Bovine Dams During Early Gestation on Postnatal Growth, Carcass and Organ Characteristics, and Gene Expression in Adipose Tissue and Muscle. J Anim Sci (2010) 88:3251–61. doi: 10.2527/jas.2009-2512
- Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab (2004) 89:2548–56. doi: 10.1210/jc.2004-0395
- Albrecht EA, Schering L, Liu Y, Komolka K, Kühn C, Wimmers K, et al. Factors Influencing Bovine Intramuscular Adipose Tissue Development and Cellularity. J Anim Sci (2017) 95:2244–54. doi: 10.2527/jam2016-0786
- Ferrell CL, Jenkins TG. Cow Type and the Nutritional Environment: Nutritional Aspects. J Anim Sci (1985) 61:725–41. doi: 10.2527/jas1985.613725x
- Blaxter KL, Wainman FW, Davidson JL. The Voluntary Intake of Food by Sheep and Cattle in Relation to Their Energy Requirements for Maintenance. *Anim Prod* (1966) 8:75–83. doi: 10.1017/S0003356100037739
- Labussière E, van Milgen J, de Lange CFM, Noblet J. Maintenance Energy Requirements of Growing Pigs and Calves Are Influenced by Feeding Level. J Nutr (2011) 141:1855–61. doi: 10.3945/jn.111.141291
- Symonds ME, Stephenson T, Gardner DS, Budge H. Long-Term Effects of Nutritional Programming of the Embryo and Fetus: Mechanisms and Critical Windows. *Reprod Fertil Dev* (2007) 19:53–63. doi: 10.1071/rd06130
- Cheng L, Wang J, Dai H, Duan Y, An Y, Shi L, et al. Brown and Beige Adipose Tissue: A Novel Therapeutic Strategy for Obesity and Type 2 Diabetes Mellitus. *Adipocyte* (2021) 10(1):48–65. doi: 10.1080/21623945.2020.1870060
- Jennings TD, Gonda MG, Underwood KR, Wertz-Lutz AE, Blair AD. The Influence of Maternal Nutrition on Expression of Genes Responsible for Adipogenesis and Myogenesis in the Bovine Fetus. *Animal* (2016) 10:1697– 705. doi: 10.1017/S1751731116000665
- Redmer DA, Wallace JM, Reynolds LP. Effect of Nutrient Intake During Pregnancy on Fetal and Placental Growth and Vascular Development. *Domest Anim Endocrinol* (2004) 27:199–217. doi: 10.1016/j.domaniend.2004.06.006
- 53. Martin GS, Carstens GE, Taylor TL, Sweatt CR, Eli AG, Lunt DK, et al. Prepartum Protein Restriction Does Not Alter Norepinephrine-Induced Thermogenesis or Brown Adipose Tissue Function in Newborn Calves. J Nutr (1997) 127:1929–37. doi: 10.1093/jn/127.10.1929
- 54. Farvid MS, Ng TWK, Chan DC, Barrett PHR, Watts GF. Association of Adiponectin and Resistin With Adipose Tissue Compartments, Insulin Resistance and Dyslipidaemia. *Diabetes Obes Metab* (2005) 7:406–13. doi: 10.1111/j.1463-1326.2004.00410.x

- Robelin J. Cellularity of Bovine Adipose Tissues: Developmental Changes From 15 to 65 Percent Mature Weight. J Lipid Res (1981) 22:452–7. doi: 10.1016/S0022-2275(20)34959-2
- Gnanalingham MG, Mostyn A, Symonds ME, Stephenson T. Ontogeny and Nutritional Programming of Adiposity in Sheep: Potential Role of Glucocorticoid Action and Uncoupling Protein-2. Am J Physiol Regul Integr Comp Physiol (2005) 289:R1407–15. doi: 10.1152/ajpregu.00375.2005
- Muhlhausler BS, Duffield JA, McMillen IC. Increased Maternal Nutrition Stimulates Peroxisome Proliferator Activated Receptor-Gamma, Adiponectin, and Leptin Messenger Ribonucleic Acid Expression in Adipose Tissue Before Birth. *Endocrinology* (2007) 148:878–85. doi: 10.1210/en.2006-1115
- Ladeira MM, Schoonmaker JP, Gionbelli MP, Dias JCO, Gionbelli TRS, Carvalho JRR, et al. Nutrigenomics and Beef Quality: A Review About Lipogenesis. *Int J Mol Sci* (2016) 17:918. doi: 10.3390/ijms17060918
- Yau SW, Henry BA, Russo VC, McConell GK, Clarke IJ, Werther GA, et al. Leptin Enhances Insulin Sensitivity by Direct and Sympathetic Nervous System Regulation of Muscle IGFBP-2 Expression: Evidence from Nonrodent Models. *Endocrinology* (2014) 155:2133–43. doi: 10.1210/ en.2013-2099
- Carvalho E, Kotani K, Peroni OD, Kahn BB. Adipose-Specific Overexpression of GLUT4 Reverses Insulin Resistance and Diabetes in Mice Lacking GLUT4 Selectively in Muscle. *Am J Physiol Endocrinol Metab* (2005) 289:E551–61. doi: 10.1152/ajpendo.00116.2005
- Clarke SL, Robinson CE, Gimble JM. CAAT/enhancer Binding Proteins Directly Modulate Transcription From the Peroxisome Proliferator-Activated Receptor Gamma 2 Promoter. *Biochem Biophys Res Commun* (1997) 240:99–103. doi: 10.1006/bbrc.1997.7627
- 62. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, et al. Cross-Regulation of C/EBP Alpha and PPAR Gamma Controls the Transcriptional Pathway of Adipogenesis and Insulin Sensitivity. *Mol Cell* (1999) 3:151–8. doi: 10.1016/s1097-2765(00)80306-8
- Lawrence TLJ, Fowler VR, Novakofski JE. Chapter 4. Tissues: Basic Structure and Growth. In: Growth, Growth of Farm Animals, 3rd Ed. London, UK: CAB International (2012). p. 139–73.
- Wang GX, Meyer JG, Cai W, Softic S, Li ME, Verdin E, et al. Regulation of UCP1 and Mitochondrial Metabolism in Brown Adipose Tissue by Reversible Succinylation. *Mol Cell* (2019) 74:844–57. doi: 10.1016/j.molcel.2019.03.021
- Ikeda K, Maretich P, Kajimura S. The Common and Distinct Features of Brown and Beige Adipocytes. *Trends Endocrinol Metab* (2018) 29:191–200. doi: 10.1016/j.tem.2018.01.001
- Chouchani ET, Kazak L, Spiegelman BM. New Advances in Adaptive Thermogenesis: UCP1 and Beyond. *Cell Metab* (2019) 29:27–37. doi: 10.1016/j.cmet.2018.11.002
- 67. Landis MD, Cars tens GE, MPhil EG, Randal RD, Green KK, Slay L, et al. Ontogenic Development of Brown Adipose Tissue in Angus and Brahman Fetal Calves. J Anim Sci (2002) 80:591–601. doi: 10.2527/2002.803591x
- Gardner DS, Tingey K, Van Bon BW, Ozanne SE, Wilson V, Dandrea J, et al. Programming of Glucose-Insulin Metabolism in Adult Sheep After Maternal Undernutrition. *Am J Physiol Regul Integr Comp Physiol* (2005) 289:R947–54. doi: 10.1152/ajpregu.00120.2005
- 69. Bispham J, Gardner DS, Gnanalingham MG, Stephenson T, Symonds ME, Budge H. Maternal Nutritional Programming of Fetal Adipose Tissue Development: Differential Effects on Messenger Ribonucleic Acid Abundance for Uncoupling Proteins and Peroxisome Proliferator-Activated and Prolactin Receptors. *Endocrinology* (2005) 146:3943–9. doi: 10.1210/en.2005-0246
- Gupta RK, Arany Z, Seale P, Mepani RJ, Ye L, Conroe HM, et al. Transcriptional Control of Preadipocyte Determination by Zfp423. *Nature* (2010) 464:619–23. doi: 10.1038/nature08816
- Shao M, Hepler C, Vishvanath L, MacPherson KA, Busbuso NC, Gupta RK. Fetal Development of Subcutaneous White Adipose Tissue is Dependent on Zfp423. *Mol Metab* (2017) 6:111–24. doi: 10.1016/j.molmet.2016.11.009

- Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, et al. PRDM16 Controls a Brown Fat/Skeletal Muscle Switch. *Nature* (2008) 454:961–7. doi: 10.1038/nature07182
- Lepper C, Fan CM. Inducible Lineage Tracing of Pax7-Descendant Cells Reveals Embryonic Origin of Adult Satellite Cells. *Genesis* (2010) 48:424–36. doi: 10.1002/dvg.20630
- 74. Yang QY, Liang JF, Rogers CJ, Zhao JX, Zhu MJ, Du M. Maternal Obesity Induces Epigenetic Modifications to Facilitate Zfp423 Expression and Enhance Adipogenic Differentiation in Fetal Mice. *Diabetes* (2013) 62:3727– 35. doi: 10.2337/db13-0433
- 75. Liang X, Yang Q, Zhang L, Maricelli JW, Rodgers BD, Zhu MJ, et al. Maternal High-Fat Diet During Lactation Impairs Thermogenic Function of Brown Adipose Tissue in Offspring Mice. *Sci Rep* (2016) 6:34345. doi: 10.1038/ srep34345
- Hilton C, Neville MJ, Karpe F. MicroRNAs in Adipose Tissue: Their Role in Adipogenesis and Obesity. Int J Obes (Lond) (2013) 37:325–32. doi: 10.1038/ ijo.2012.59
- Price NL, Fernández-Hernando C. miRNA Regulation of White and Brown Adipose Tissue Differentiation and Function. *Biochim Biophys Acta* (2016) 1861:2104–10. doi: 10.1016/j.bbalip.2016.02.010
- Spiegelman BM, Puigserver P, Wu Z. Regulation of Adipogenesis and Energy Balance by PPARgamma and PGC-1. *Int J Obes Relat Metab Disord* (2000) 4: S8–10. doi: 10.1038/sj.ijo.0801492
- Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A Role of miR-27 in the Regulation of Adipogenesis. *FEBS J* (2009) 276:2348–58. doi: 10.1111/j.1742-4658.2009.06967.x
- Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikantan S, et al. miR-130 Suppresses Adipogenesis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma Expression. *Mol Cell Biol* (2011) 31:626–38. doi: 10.1128/ MCB.00894-10
- Sun L, Trajkovski M. MiR-27 Orchestrates the Transcriptional Regulation of Brown Adipogenesis. *Metabolism* (2014) 63(2):272–82. doi: 10.1016/ j.metabol.2013.10.004
- Gesta S, Tseng YH, Kahn CR. Developmental Origin of Fat: Tracking Obesity to its Source. *Cell* (2007) 131:242–56. doi: 10.1016/j.cell.2007.10.004
- Yan X, Zhu MJ, Dodson MV, Du M. Developmental Programming of Fetal Skeletal Muscle and Adipose Tissue Development. J Genom (2013) 1:29–38. doi: 10.7150/jgen.3930
- Burak K, Lamoureux L, Boese A, Majer A, Saba R, Niu Y, et al. MicroRNA-16 Targets mRNA Involved in Neurite Extension and Branching in Hippocampal Neurons During Presymptomatic Prion Disease. *Neurobiol Dis* (2018) 112:1– 13. doi: 10.1016/j.nbd.2017.12.011
- Gebert LFR, MacRae IJ. Regulation of microRNA Function in Animals. Nat Rev Mol Cell Biol (2019) 20:21–37. doi: 10.1038/s41580-018-0045-7

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Otomaru, Oshima, Goto, Oshima, Muroya, Sano, Roh and Gotoh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.